Use: Labeled indications
- Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only).
- Complicated intra-abdominal infections (adult and pediatric patients).
- Bacterial meningitis (pediatric patients 3 months of age and older only).
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Meropenem for injection is a penem antibacterial indicated for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only).
(1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of meropenem for injection and other antibacterial drugs, meropenem for injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Complicated Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of Age and Older Only) Meropenem for injection is indicated for the treatment of complicated skin and skin structure infections (cSSSI) due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Complicated Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of Age and Older Only) Meropenem for injection is indicated for the treatment of bacterial meningitis caused by Haemophilus influenzae, Neisseria meningitidis and penicillin-susceptible isolates of Streptococcus pneumoniae. Meropenem for injection has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of meropenem for injection and other antibacterial drugs, meropenem for injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Contraindications
- Known hypersensitivity to product components or other drugs in the same class
- Anaphylactic reactions to beta-lactams
Contraindications (US label) US FDA label
4 CONTRAINDICATIONS Meropenem is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta (β)-lactams. Known hypersensitivity to product components or anaphylactic reactions to β-lactams. (4)
Dosing: Adult
- Complicated skin and skin structure infections: 500 mg IV every 8 hours (1 g every 8 hours if Pseudomonas aeruginosa)
- Complicated intra-abdominal infections: 1 g IV every 8 hours
- Administration: Infuse over 15 to 30 minutes; 1 g doses may also be given as an IV bolus (5 to 20 mL) over 3 to 5 minutes
- CrCl 50 mL/min or less: 26–50: usual dose every 12 hours; 10–25: half dose every 12 hours; below 10: half dose every 24 hours
- 500 mg every 8 hours by intravenous infusion over 15 to 30 minutes for complicated skin and skin structure infections (cSSSI) for adult patients. When treating infections caused by Pseudomonas aeruginosa, a dose of 1 gram every 8 hours is recommended. (2.1)
- 1 gram every 8 hours by intravenous infusion over 15 minutes to 30 minutes for intra-abdominal infections for adult patients. (2.1)
- 1 gram every 8 hours by intravenous bolus injection (5 mL to 20 mL) over 3 minutes to 5 minutes for adult patients. (2.1)
- Dosage should be reduced in adult patients with renal impairment. (2.2)
- Recommended Meropenem for Injection Dosage Schedule for Adult Patients with Renal Impairment Creatinine Clearance (mL/min) Dose (dependent on type of infection) Dosing Interval Greater than 50 Recommended dose (500 mg cSSSI and 1 gram Intra-abdominal) Every 8 hours 26-50 Recommended dose Every 12 hours 10-25 One-half recommended dose Every 12 hours Less than 10 One-half recommended dose Every 24 hours Pediatric patients 3 months of age and older Recommended Meropenem for Injection Dosage Schedule for Pediatric Patients 3 Months of Age and Older with Normal Renal Function (2.3)
- Type of Infection Dose (mg/kg) Up to a Maximum Dose Dosing Interval Complicated skin and skin structure* 10 500 mg Every 8 hours Intra-abdominal 20 1 gram Every 8 hours Meningitis 40 2 gram Every 8 hours - Intravenous …
2.1 Adult Patients
2.1 Adult Patients The recommended dose of meropenem for injection is 500 mg given every 8 hours for skin and skin structure infections and 1 gram given every 8 hours for intra-abdominal infections. When treating complicated skin and skin structure infections caused by P. aeruginosa, a dose of 1 gram every 8 hours is recommended.
Meropenem for injection should be administered by intravenous infusion over approximately 15 minutes to 30 minutes. Doses of 1 gram may also be administered as an intravenous bolus injection (5 mL to 20 mL) over approximately 3 minutes to 5 minutes.
2.2 Use in Adult Patients with Renal Impairment
2.2 Use in Adult Patients with Renal Impairment Dosage should be reduced in patients with creatinine clearance of 50 mL/min or less. (See dosing Table below.) When only serum creatinine is available, the following formula (Cockcroft and Gault equation) 1 may be used to estimate creatinine clearance. Males: Creatinine Clearance (mL/min) = Weight (kg) × (140 - age) 72 × serum creatinine (mg/dL) Females: 0.85 × above value Table 1: Recommended Meropenem for Injection Dosage Schedule for Adult Patients with Renal Impairment Creatinine Clearance (mL/min) Dose (dependent on type of infection) Dosing Interval Greater than 50 Recommended dose (500 mg cSSSI and 1 gram Intra-abdominal) Every 8 hours 26-50 Recommended dose Every 12 hours 10-25 One-half recommended dose Every 12 hours Less than 10 One-half recommended dose Every 24 hours There is inadequate information regarding the use of meropenem for injection in patients on hemodialysis or peritoneal dialysis.
2.3 Use in Pediatric Patients
2.3 Use in Pediatric Patients Pediatric Patients 3 Months of Age and Older For pediatric patients 3 months of age and older, the meropenem for injection dose is 10 mg/kg, 20 mg/kg or 40 mg/kg every 8 hours (maximum dose is 2 grams every 8 hours), depending on the type of infection (cSSSI, cIAI, intra-abdominal infection or meningitis). See dosing Table 2 below.
For pediatric patients weighing over 50 kg administer meropenem for injection at a dose of 500 mg every 8 hours for cSSSI, 1 gram every 8 hours for cIAI and 2 grams every 8 hours for meningitis. Administer meropenem for injection as an intravenous infusion over approximately 15 minutes to 30 minutes or as an intravenous bolus injection (5 mL to 20 mL) over approximately 3 minutes to 5 minutes.
There is limited safety data available to support the administration of a 40 mg/kg (up to a maximum of 2 grams) bolus dose. Table 2: Recommended Meropenem for Injection Dosage Schedule for Pediatric Patients 3 Months of Age and Older with Normal Renal Function Type of Infection Dose (mg/kg) Up to a Maximum Dose Dosing Interval Complicated skin and skin structure infections 10 500 mg Every 8 hours Complicated intra-abdominal infections 20 1 gram Every 8 hours Meningitis 40 2 grams Every 8 hours There is no experience in pediatric patients with renal impairment.
When treating cSSSI caused by P. aeruginosa, a dose of 20 mg/kg (or 1 gram for pediatric patients weighing over 50 kg) every 8 hours is recommended. Pediatric Patients Less Than 3 Months of Age For pediatric patients (with normal renal function) less than 3 months of age, with complicated intra-abdominal infections, the meropenem for injection dose is based on gestational age (GA) and postnatal age (PNA).
See dosing Table 3 below. Meropenem for injection should be given as intravenous infusion over 30 minutes. Table 3: Recommended Meropenem for Injection Dosage Schedule for Pediatric Patients Less than 3 Months of Age with Complicated Intra-abdominal Infections and Normal Renal Function Age Group Dose (mg/kg) Dose Interval Infants less than 32 weeks GA and PNA less than 2 weeks 20 Every 12 hours Infants less than 32 weeks GA and PNA 2 weeks and older 20 Every 8 hours Infants 32 weeks and older GA and PNA less than 2 weeks 20 Every 8 hours Infants 32 weeks and older GA and PNA 2 weeks and older 30 Every 8 hours There is no experience in pediatric patients with renal impairment.
2.4 Preparation and Administration of Meropenem for Injection Important
2.4 Preparation and Administration of Meropenem for Injection Important Administration Instructions: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. For Intravenous Bolus Administration Re-constitute injection vials (500 mg and 1 gram) with sterile Water for Injection (see Table 4 below).
Shake to dissolve and let stand until clear. Table 4: Volume of Sterile Water for Injection for Reconstitution of Injection Vials Vial Size Amount of Diluent Added (mL) Approximate Withdrawable Volume (mL) Approximate Average Concentration (mg/mL) 500 mg 10 10 50 1 gram 20 20 50 For Infusion Injection vials (500 mg and 1 gram) may be directly re-constituted with a compatible infusion fluid.
Alternatively, an injection vial may be re-constituted, then the resulting solution added to an intravenous container and further diluted with an appropriate infusion fluid [see Dosage and Administration (2.5), (2.6)]. Do not use flexible container in series connections.
2.5 Compatibility
2.5 Compatibility Compatibility of meropenem for injection with other drugs has not been established. Meropenem for injection should not be mixed with or physically added to solutions containing other drugs.
2.6 Stability and Storage
2.6 Stability and Storage Freshly prepared solutions of meropenem for injection should be used. However, re-constituted solutions of meropenem for injection maintain satisfactory potency under the conditions described below. Solutions of intravenous meropenem for injection should not be frozen. Intravenous Bolus Administration Meropenem for injection vials re-constituted with sterile Water for Injection for bolus administration (up to 50 mg/mL of meropenem for injection) may be stored for up to 3 hours at up to 25°C (77°F) or for 13 hours at up to 5°C (41°F).
Intravenous Infusion Administration Solutions prepared for infusion (meropenem for injection concentrations ranging from 1 mg/mL to 20 mg/mL) re-constituted with Sodium Chloride Injection 0.9% may be stored for 1 hour at up to 25°C (77°F) or 15 hours at up to 5°C (41°F). Solutions prepared for infusion (meropenem for injection concentrations ranging from 1 mg/mL to 20 mg/mL) re-constituted with Dextrose Injection 5% should be used immediately.
Dosing: Altered kidney function
Meropenem clearance tracks creatinine clearance (CrCl). The US label reduces the dose or extends the interval when CrCl is 50 mL/min or less; it says information is inadequate for hemodialysis or peritoneal dialysis, although meropenem is removed by hemodialysis. In critical illness, prolonged or continuous infusion of the same daily dose may be used per local protocol (label regimens are 30-minute infusions).
Kidney function measure: Label uses creatinine clearance (CrCl, mL/min; Cockcroft–Gault).
Show full dosing details
- CrCl ≥60 mL/min
- Recommended dose every 8 hours (label: CrCl >50; 500 mg for complicated skin infections, 1 g for intra-abdominal infection).
- CrCl 30–59 mL/min
- CrCl >50: every 8 hours. CrCl 26–50: recommended dose every 12 hours (label).
- CrCl 15–29 mL/min
- CrCl 26–50: full dose every 12 hours. CrCl 10–25: one-half dose every 12 hours (label).
- CrCl <15 mL/min (not on dialysis)
- CrCl 10–25: one-half dose every 12 hours. CrCl <10: one-half dose every 24 hours (label).
- Hemodialysis (intermittent)
- Label: information in hemodialysis is inadequate for a dose recommendation. Meropenem is removed by hemodialysis; give any dose after the session. Current literature does not support thrice-weekly post-hemodialysis meropenem (Tsai 2025). Dose with specialist input.
- Peritoneal dialysis
- Inadequate information in label. For PD-associated peritonitis (ISPD 2022): intraperitoneal intermittent 500 mg daily (long dwell in APD) or 1,000 mg daily (short dwell in CAPD); continuous maintenance dose 125 mg/L in each exchange (no loading dose listed). Specialist input.
- CRRT
- Not in label. Published CRRT regimens: 1 g every 8 hours at higher effluent rates (about 35 mL/kg/h); 1 g every 12 hours at lower effluent for susceptible organisms; consider extended infusion; adjust to residual function and MIC (Li 2020).
- Dialyzable? Yes: readily dialyzable (label).
- Monitoring Seizure risk higher in kidney impairment and central nervous system disease; do not combine with valproate (label class warnings).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Usual pediatric dosing.
- eGFR 30–59
- No experience in pediatric patients with renal impairment (label). Specialist input.
- eGFR 15–29
- No experience in pediatric patients with renal impairment (label). Specialist input.
- eGFR <15 (not on dialysis)
- No experience in pediatric patients with renal impairment (label). Specialist input.
- Hemodialysis (intermittent)
- No experience (label).
- Peritoneal dialysis
- No experience.
- CRRT
- No experience.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
2.2 Use in Adult Patients with Renal Impairment Dosage should be reduced in patients with creatinine clearance of 50 mL/min or less. (See dosing Table below.) When only serum creatinine is available, the following formula (Cockcroft and Gault equation) 1 may be used to estimate creatinine clearance. Males: Creatinine Clearance (mL/min) = Weight (kg) × (140 - age) 72 × serum creatinine (mg/dL) Females: 0.85 × above value Table 1: Recommended Meropenem for Injection Dosage Schedule for Adult Patients with Renal Impairment Creatinine Clearance (mL/min) Dose (dependent on type of infection) Dosing Interval Greater than 50 Recommended dose (500 mg cSSSI and 1 gram Intra-abdominal) Every 8 hours 26-50 Recommended dose Every 12 hours 10-25 One-half recommended dose Every 12 hours Less than 10 One-half recommended dose Every 24 hours There is inadequate information regarding the use of meropenem for injection in patients on hemodialysis or peritoneal dialysis.
8.6 Patients with Renal Impairment Dosage adjustment is necessary in patients with creatinine clearance 50 mL/min or less [see Dosage and Administration (2.2), Warnings and Precautions (5.8), Clinical Pharmacology (12.3)].
Patients with Renal Impairment Pharmacokinetic studies with meropenem in patients with renal impairment have shown that the plasma clearance of meropenem correlates with creatinine clearance. Dosage adjustments are necessary in subjects with renal impairment (creatinine clearance 50 mL/min or less) [see Dosage and Administration (2.2), Use in Specific Populations (8.6)]. Meropenem is hemodialyzable. However, there is no information on the usefulness of hemodialysis to treat overdosage [see Overdosage (10)].
Dosing: Pediatric
- Approved ages
- All ages for complicated intra-abdominal infections; 3 months and older for complicated skin infections and bacterial meningitis (vial label 8.4).
- Usual dose
- Complicated skin infections 10 mg/kg (max 500 mg) every 8 hours (20 mg/kg if Pseudomonas aeruginosa); intra-abdominal infections 20 mg/kg (max 1 g) every 8 hours; meningitis 40 mg/kg (max 2 g) every 8 hours. Over 50 kg: adult doses (label).
- Maximum dose
- 2 g every 8 hours (meningitis) (label).
- Neonates
- Under 3 months, complicated intra-abdominal infection, normal kidney function (label 2.3): GA under 32 weeks and PNA under 2 weeks, 20 mg/kg every 12 hours; GA under 32 weeks and PNA 2 weeks or older, 20 mg/kg every 8 hours; GA 32 weeks or older and PNA under 2 weeks, 20 mg/kg every 8 hours; GA 32 weeks or older and PNA 2 weeks or older, 30 mg/kg every 8 hours. Infuse over 30 minutes. No experience with kidney impairment.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of meropenem have been established for pediatric patients 3 months of age and older with complicated skin and skin structure infections and bacterial meningitis, and for pediatric patients of all ages with complicated intra-abdominal infections. Skin and Skin Structure Infections Use of meropenem in pediatric patients 3 months of age and older with complicated skin and skin structure infections is supported by evidence from an adequate and well-controlled study in adults and additional data from pediatric pharmacokinetics studies [see Indications and Usage (1.3), Dosage and Administration (2.3), Adverse Reactions (6.1), Clinical Pharmacology (12.3), Clinical Studies (14.1)].
Intra-abdominal Infections Use of meropenem in pediatric patients 3 months of age and older with intra-abdominal infections is supported by evidence from adequate and well-controlled studies in adults with additional data from pediatric pharmacokinetics studies and controlled clinical trials in pediatric patients. Use of meropenem in pediatric patients less than 3 months of age with intra-abdominal infections is supported by evidence from adequate and well-controlled studies in adults with additional data from a pediatric pharmacokinetic and safety study [see Indications and Usage (1.2), Dosage and Administration (2.3), Adverse Reactions (6.1), Clinical Pharmacology (12.3), Clinical Studies (14.2)].
Bacterial Meningitis Use of meropenem in pediatric patients 3 months of age and older with bacterial meningitis is supported by evidence from adequate and well-controlled studies in the pediatric population [see Indications and Usage (1.3), Dosage and Administration (2.3), Adverse Reactions (6.1), Clinical Pharmacology (12.3), Clinical Studies (14.3)].
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the total number of subjects in clinical studies of meropenem, approximately 1100 (30%) were 65 years of age and older, while 400 (11%) were 75 years and older. Additionally, in a study of 511 patients with complicated skin and skin structure infections, 93 (18%) were 65 years of age and older, while 38 (7%) were 75 years and older.
No overall differences in safety or effectiveness were observed between these subjects and younger subjects; spontaneous reports and other reported clinical experience have not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Meropenem is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with renal impairment.
Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. A pharmacokinetic study with meropenem in elderly patients has shown a reduction in the plasma clearance of meropenem that correlates with age-associated reduction in creatinine clearance [see Clinical Pharmacology (12.3)].
Administration
2.4 Preparation and Administration of Meropenem for Injection Important Administration Instructions: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. For Intravenous Bolus Administration Re-constitute injection vials (500 mg and 1 gram) with sterile Water for Injection (see Table 4 below). Shake to dissolve and let stand until clear. Table 4: Volume of Sterile Water for Injection for Reconstitution of Injection Vials Vial Size Amount of Diluent Added (mL) Approximate Withdrawable Volume (mL) Approximate Average Concentration (mg/mL) 500 mg 10 10 50 1 gram 20 20 50 For Infusion Injection vials (500 mg and 1 gram) may be directly re-constituted with a compatible infusion fluid. Alternatively, an injection vial may be re-constituted, then the resulting solution added to an intravenous container and further diluted with an appropriate infusion fluid [ see Dosage and Administration (2.5) , (2.6) ] . Do not use flexible container in series connections.
2.5 Compatibility Compatibility of meropenem for injection with other drugs has not been established. Meropenem for injection should not be mixed with or physically added to solutions containing other drugs.
US FDA labelDosage forms
Philippines
- Powder for injection: 1 g, 500 mg, 500 mg 500 mg
- Powder for solution for injection: 1 g, 500 mg
- Powder for iv injection: 1 g, 500 mg
- Powder for i.v. injection: 500 mg
- Powder for intravenous injection: 1 g
- Powder for solution for i.v. injection: 500 mg
- Powder for solution for intravenous injection: 500 mg
- Powder for solution for iv injection/infusion: 1 g
- Powder fr injection iv: 1 g
- Sterile powder for injection: 1 g
Registered products in the Philippines
192 products registered with the Food and Drug Administration (FDA) Philippines list Meropenem as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products192
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Aemero 1000Meropenem (as trihydrate) | 1 g Powder for Injection (I.V.)20 mL USP Type II moulded glass vial with butyl rubber stopper and sealed with aluminum flip-off cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Dynasty Pharmaceuticals | DR-XY49036 | Apr 5, 2029 | |
Aemero 500Meropenem (as trihydrate) | 500 mg Powder for Injection (I.V.)20 mL USP Type II moulded glass vial with butyl rubber stopper and sealed with aluminum flip-off cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Dynasty Pharmaceuticals | DR-XY49037 | Apr 5, 2029 | |
AltacarMeropenem (as trihydrate) | 1 g Powder for Injection (IV)Clear and Colorless Glass Vial Sealed with Chlorobutyl Rubber Stopper and Purple Flip-off Seal x 20mL (5 Vials per Plastic Tray) (Box of 10's) | Rx | BCWorld Healthcare Co., Ltd.Republic of Korea | Justright Healthcare Inc.Importer: JLT Pharma Inc. | DRP-6955-06 | Jan 4, 2027 | |
Amero 1GMeropenem (As Trihydrate) | 1 g Powder For Injection (IV)20 mL-capacity USP Type I Clear glass vial with bromobutyl rubber stopper and aluminum flip-off seal (Box of l's) | Rx | Brooks Laboratories LimitedIndia | Biocare Lifesciences, Inc. | DRP-11441 | Mar 14, 2027 | |
Amero 500Meropenem (as trihydrate) | 500 mg Powder for Injection (IV)Type I Transparent Flint Glass Vial x 20 mL (Box of 1's) | Rx | ZEISS PHARMACEUTICALS PVT. LTD.India | BIOCARE LIFESCIENCES, INC.Importer: Glenmark Philippines, Inc.Trader: GLENMARK PHARMACEUTICALS LTD. | DRP-7690-02 | Feb 6, 2028 | |
Amero 500Meropenem (As Trihydrate) | 500mg Powder For Injection (IV)20 mL-capacity USP Type I Clear glass vial with bromobutyl rubber stopper and aluminum flip-off seal (Box of 1's) | Rx | Brooks Laboratories LimitedIndia | Biocare Lifesciences, Inc. | DRP-11442 | Mar 14, 2027 | |
Amero IVMeropenem (as trihydrate) | 1 g Powder for Injection (IV)Type I Transparent Flint Glass Vial x 20 mL Box of 1's | Rx | ZEISS PHARMACEUTICALS PVT. LTD.India | BIOCARE LIFESCIENCES, INC.Importer: Glenmark Philippines, Inc.Trader: GLENMARK PHARMACEUTICALS LTD. | DRP-7691-01 | Feb 7, 2028 | |
AmsopenMeropenem (as trihydrate) | 1 g powder for injection (IV)One (1) box contains: USP Type II Colorless Glass Vial (as active) + USP Type II Colorless Glass Ampoule in 10 mL (net content as diluent) x 2's wrapped in Alu/Clear PVC | Rx | Aristopharma Ltd.Bangladesh | Amson PharmaceuticalsImporter: Sahar International Trading, Inc. | DRP-10152-01 | Sep 5, 2028 | |
AmsopenMeropenem (as trihydrate) | 500 mg Powder for Injection (IV)One (1) box contains: USP Type II Colorless Glass Vial (as active) + USP Type II Colorless Glass Ampoule in 10 mL (net content as diluent) x 2's wrapped in Alu/Clear PVC | Rx | Aristopharma Ltd.Bangladesh | Amson PharmaceuticalsImporter: Sahar International Trading Inc. | DRP-10150-01 | Sep 5, 2028 | |
AnagrapemMeropenem (as trihydrate) | 1 g Powder for Injection (I.V.)USP Type I Clear and Tubular Glass vial with grey bromo butyl rubber stopper and sky blue plain flip-off aluminum seal x 30 mL Box of 1's | Rx | Mepromax Lifesciences Pvt. Ltd.India | Nordlich Pharma, Inc.Importer: Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd. | DRP-10557-04 | Dec 15, 2029 | |
Anagrapem 500Meropenem (as trihydrate) | 500 mg Powder for Injection (I.V.)USP Type I Clear, Tubular Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal x 20 mL (Box of 1’s) | Rx | Mepromax Lifesciences Pvt. Ltd.India | Nordlich Pharma, Inc.Importer: Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd. | DRP-12129-04 | Dec 15, 2029 | |
AropenMeropenem (as trihydrate) | 1 g Powder for Injection (IV)One (1) box contains: USP Type II Colorless Glass Vial (as active) + USP Type II Colorless Glass Ampoule x 10 mL (net content as diluent) x 2's wrapped in Alu/Clear PVC | Rx | Aristopharma Ltd.Bangladesh | SAHAR INTERNATIONAL TRADING, INC. | DRP-10152 | Sep 5, 2028 | |
AropenMeropenem (as trihydrate) | 500 mg Powder for Injection (IV)One (1) box contains: USP Type II Colorless Glass Vial (as active) + USP Type II Colorless Glass Ampoule in 10 mL (net content as diluent) x 2's wrapped in Alu/Clear PVC | Rx | Aristopharma Ltd.Bangladesh | Sahar International Trading, Inc. | DRP-10150 | Sep 5, 2028 | |
ArunemMeropenem (as trihydrate) | 1 g Powder for Injection (I.V.)USP Type I Clear and Tubular Glass vial with grey bromo butyl rubber stopper and sky blue plain flip-off aluminum seal x 30 mL (Box of 1's) | Rx | Mepromax Lifesciences Pvt. Ltd.India | Neo-Care PhilippinesImporter: Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd. | DRP-10557-05 | Dec 15, 2029 | |
ArunemMeropenem (as trihydrate) | 500 mg Powder for Injection (I.V.)USP Type I Clear, Tubular Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal x 20 mL (Box of 1's) | Rx | Mepromax Lifesciences Pvt. Ltd.India | Neo-Care PhilippinesImporter: Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd. | DRP-12129-03 | Dec 15, 2029 | |
B-PENEM IVMeropenem (As Trihydrate) | 1 g Powder For Injection ( IV)20 mL-capacity USP Type I Clear glass vial with bromobutyl rubber stopper and aluminum flip-off seal (Box of 1's) | Rx | Brooks Laboratories LimitedIndia | Biocare Lifesciences, Inc. | DRP-11443 | Mar 14, 2027 | |
B-PENEM IVMeropenem (as trihydrate) | 500 mg Powder for Injection (IV)20 mL-capacity USP Type I Clear glass vial with bromobutyl rubber stopper and aluminum flip-off seal (Box of l's) | Rx | Brooks Laboratories LimitedIndia | Biocare Lifesciences, Inc. | DRP-12574 | Sep 14, 2027 | |
BDMERO 1000Meropenem (as trihydrate) | 1 g Powder for Injection (I.V.)USP Type I Clear and Tubular Glass vial with grey bromo butyl rubber stopper and sky blue plain flip-off aluminum seal x 30 mL Box of 1's | Rx | Mepromax Lifesciences Pvt. Ltd.India | Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd. | DRP-10557 | Dec 15, 2029 | |
BDMERO 500Meropenem (as trihydrate) | 500 mg Powder for Injection (I.V.)USP Type I Clear, Tubular Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal x 20 mL (Box of 1's) | Rx | Mepromax Lifesciences Pvt. Ltd.India | Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd. | DRP-12129 | Dec 15, 2029 | |
BiopenemMeropenem (as trihydrate) | 1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's) | Rx | Daffodills Pharmaceuticals Ltd.India | Medwise, Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-7074-07 | Mar 6, 2027 | |
CanemMeropenem (As Trihydrate) | 1 g Powder for Injection (IV)20 mL USP Type I Flint Glass Vial (Box of 1's) | Rx | Shamshree Lifesciences Ltd.India | Britton Distributions Inc.Importer: Genpharm, Inc.Trader: Cachet Pharmaceuticals Pvt., Ltd. | DR-XY38582 | Jan 27, 2030 | |
CarbacentMeropenem | 1 g Powder for Injection (IV)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1's (Box of 1 's) | Rx | Uni MedicolabsIndia | Central West Medicale Inc.Importer: Greencore Pharma Inc. | DRP-11927-04 | May 20, 2027 | |
CarmepemMeropenem (as trihydrate) | 1 g Powder for Injection (I.V.)Clear and Colorless Glass Vial Sealed with Chlorobutyl Rubber Stopper and Blue Flip-off Seal x 30 mL (Box of 10's) | Rx | BCWorld Healthcare Co., Ltd.Republic of Korea | Bell-Kenz Pharma Inc.Importer: JLT Pharma Inc. | DRP-6955-03 | Jan 4, 2032 | |
CarmepemMeropenem (as trihydrate) | 500 mg Powder for Injection (IV)20 mL USP Type I Clear and Colorless Glass Vial (Box of 10's) | Rx | BCWorld Healthcare Co., Ltd.Republic of Korea | Bell-Kenz Pharma Inc.Importer: JLT Pharma Inc. | DRP-7859-03 | May 31, 2028 | |
Carpenem-1000Meropenem (as Trihydrate) | 1 g Powder For Injection (I.V.)20 mL Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip- Off Seal Cap x 1's+ 10 mL Sterile Water for Injection in Type I Clear Colorless Glass Ampoule (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Importer: FSPC Pharmaceuticals, Inc. | DRP-13129 | Dec 5, 2027 | |
Carpenem-500Meropenem (as Trihydrate) | 500 mg Powder For Injection (I.V.)20 mL Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip- Off Seal Cap x 1's + 10 mL Sterile Water for Injection in Type I Clear Colorless Glass Ampoule (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | FSPC Pharmaceuticals, Inc. | DRP-13128 | Dec 5, 2027 | |
DexpenemMeropenem (as trihydrate) | 1 g Powder for Injection1 g in a Type I, Clear, colorless glass vial (Box of 1's) | Rx | PT DEXA MEDICAIndonesia | Glorious Dexa Mandaya, Inc | DRP-8460 | Apr 16, 2029 | |
Ecopenem-1000Meropenem | 1 g Powder for Injection (I.V.)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1 's (Box of 1 's) | Rx | Uni Medicolabs Inc.India | Planetarium Enterprise, Inc.Importer: Greencore Pharma, Inc. | DRP-11927-03 | May 20, 2027 | |
EmapenMeropenem (as trihydrate) | 1 g Powder for Solution for Injection (I.V.)USP Type II Glass Vial (Box of 1 vial) | Rx | Maxitech Pharma (Pvt) Ltd.Pakistan | Accesspoint International Trading Inc.Importer: Accesspoint International Trading, Inc. | DRP-15004 | Mar 7, 2029 | |
Emero 1000Meropenem (as trihydrate) | 1 g Powder for Injection (IV)20 mL-capacity Type I clear glass vial with bromobutyl rubber stopper and aluminum flip-off seal (Box of 1's) | Rx | Brooks Steriscience LimitedIndia | Ellebasy Medicale Group Inc.Importer: One Dexcel Pharma Inc. | DRP-12537-02 | Aug 31, 2027 | |
Emero 500Meropenem (as trihydrate) | 500 mg Powder for Injection (IV)Type I Clear Glass Vial x 20 mL with bromobutyl rubber stopper and aluminum flip-off seal (Box of 1's) | Rx | Brooks Steriscience LimitedIndia | Ellebasy Medicale Group Inc.Importer: One Dexcel Pharma Inc. | DRP-12540-02 | Aug 30, 2027 | |
Eonem 1000Meropenem (as trihydrate) | 1 g Powder For Injection (I.V.)20 mL Type I clear glass vial 10 mL ampoule Sterile Water for Injection (as diluent) [Box of 1's] | Rx | Brwan Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp. | DRP-14001 | Jun 1, 2028 | |
EopenemMeropenem | 1 g Powder For Injection (IV)Type II Clear Glass Vial with Gray Rubber Stopper and Green Aluminum Flip-Top Cap xl's (Box l's) | Rx | Zee Laboratories LimitedIndia | Importer: Eon Pharmatek, Inc. | DR-XY47718 | Feb 10, 2027 | |
EopenemMeropenem | 1 g Powder for Injection (IV)Type II Clear Glass Vial with Gray Rubber Stopper and Green Aluminum Flip-Top Cap x 1's (Box 1's) | Rx | — | Eon Pharmatek Inc. | DRP-15051 | Feb 10, 2027 | |
Ero-SMeropenem (as trihydrate) | 1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's) | Rx | Daffodills Pharmaceuticals Ltd.India | Starpharm, Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-7074-04 | Mar 6, 2027 | |
ERO-SMeropenem | 500 mg Powder for Injection (IV)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1 's (Box of 1 's) | Rx | Uni MedicolabsIndia | Starpharm, Inc.Importer: Greencore Pharma Inc. | DRP-11926-02 | May 20, 2027 | |
GoprenemMeropenem (as trihydrate) | 500 mg Powder for Injection (IV)20 mL USP Type I clear and colorless glass vial (Box of 10's) | Rx | BCWorld Healthcare Co., Ltd.Republic of Korea | Applied Pharmaceutical Distribution IncImporter: JLT Pharma Inc. | DRP-7859-02 | May 31, 2028 | |
GrobinemMeropenem (as trihydrate) | 1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's) | Rx | Daffodills Pharmaceuticals Ltd.India | Medarruz Pharmaceutical Philippines Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-7074-10 | Mar 6, 2027 | |
HyerticMeropenem (as trihydrate) | 1 g Powder for Intravenous (I.V.) InjectionUSP Type I Glass Vial x 20 mL (Box of l's) | Rx | Brooks Steriscience LimitedIndia | Orange Biotec Inc. | DRP-12721 | Sep 28, 2027 | |
Hyertic-500Meropenem (as trihydrate) | 500 mg Powder for Solution for Injection (IV)20 mL-capacity USP Type I Clear Colorless Glass Vial with Bromobutyl Rubber Stopper and Aluminum Flip-off Seal (Box of 1's) | Rx | Brooks Steriscience LimitedIndia | Orange Biotec Inc. | DRP-13605 | Mar 16, 2028 | |
KabimaxMeropenem (as trihydrate) | 1 g Powder for Solution for Injection (IV)Type III glass vial x 20 mL with rubber stopper and aluminum grey flip-off cap Box of 10's | Rx | ACS DOBFAR S.P.AItaly | Importer: Fresenius Kabi Philippines, Inc. | DR-XY46786 | Dec 20, 2029 | |
KabimaxMeropenem (as trihydrate) | 500 mg Powder for Solution for Injection (IV)Type III glass vial x 20mL with rubber stopper and aluminum purple flip-off cap (Box of 10's) | Rx | ACS DOBFAR S.P.A.Italy | Importer: Fresenius Kabi Philippines, Inc. | DR-XY46787 | Dec 20, 2029 | |
LuomepenMeropenem (as trihydrate) | 500 mg 500 mg Powder for Injection (I.M./I.V.)10 mL molded soda-lime glass vial with halogenated butyl rubber stopper and sky-blue aluminum-plastic combination cap (Box of 1's) | Rx | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.China | Luoxin Pharmaceuticals (PH) Corp. | DR-XY49360 | Mar 21, 2030 | |
Maxpenem 1000Meropenem | 1g Powder for Injection (I.V.)20 mL USP Type I Clear Moulded Glass Vial Sealed with Butyl Rubber Stopper and Blue Aluminum Plastic Cap (Box of 1's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | Dreamax Incorporated | DRP-17074 | Sep 24, 2030 | |
MepemMeropenem (as trihydrate) | 1 g Powder for Injection (I.V.)USP Type I Clear and Colorless Glass Vial with Chlorobutyl Rubber Stopper and Blue Flip-off Seal x 30 mL (Box of 10's) | Rx | BCWorld Healthcare Co., Ltd.Republic of Korea | Uni-Pharma Phils., Inc.Importer: JLT Pharma Inc. | DRP-6955 | Jan 4, 2032 | |
MepemMeropenem (as trihydrate) | 500 mg Powder for Injection (IV)20 mL USP Type I Clear and Colorless Glass Vial (Box of 10's) | Rx | BCWorld Healthcare Co., Ltd.Republic of Korea | Uni-Pharma Phils., Inc.Importer: JLT Pharma Inc. | DRP-7859 | May 31, 2028 | |
MepenemMeropenem (As Trihydrate) | 1 g Powder For Injection (IV)USP Type I Colorless Glass Vial with Aluminum Seal and Violet Flip-off Cap + LDPE Vial x 10 mL as Diluent (Box of 1 Vial + 2 Diluent) | Rx | Singapore Pharmawealth Lifesciences, Inc.Philippines | Importer: A. Menarini Philippines, Inc. | DR-XY37067 | Mar 2, 2027 | |
MepenemMeropenem (As Trihydrate) | 500 mg Powder For Injection (IV)USP Type I Colorless Glass Vial with Aluminum Seal and Purple Flip-off Cap + LDPE Vial x 10 mL as Diluent (Box of 1 Vial + Diluent) | Rx | Singapore Pharmawealth Lifesciences, Inc.Philippines | Trader: Phil. Pharmawealth, Inc. | DR-XY37068 | Mar 2, 2027 | |
Merilollen-BIMeropenem (as trihydrate) | 1g Powder for Solution for Injection (IV)Clear glass vial with gray bromobutyl rubber stopper and aluminum seal (Box of 1's) | Rx | Belco PharmaIndia | Ollen Pharma Trading Inc. | DRP-17395 | Dec 10, 2031 | |
MerivaMeropenem (as trihydrate) | 1 g Powder for Injection (IV)Individually boxed 30 mL-capacity USP Type I clear and colorless glass vial sealed with grey bromobutyl rubber stopper and violet flip-off seal (Box of 10's) | Rx | Zeiss Pharmaceuticals Pvt. Ltd.India | Importer: Claris Lifesciences Philippines, Inc.Trader: Baxter Pharmaceuticals India Private Limited | DRP-2151 | Apr 30, 2027 | |
Mero-XMeropenem (as Trihydrate) | 1 g Powder For Solution for Injection (IV)Type I clear glass vial x 30 mL with rubber stopper and violet plastic flip-off seal (Box of 1's) | Rx | RF Life Science Private LimitedIndia | Exa Life Care Pharma Inc. | DRP-18131 | May 11, 2031 | |
MerobactMeropenem (as trihydrate) | 1 g Powder for Injection (IV)USP Type I clear glass vial with grey bromobutyl rubber stopper, aluminum seal, and flip-off cap + clear glass ampoule x 5 mL Sterile Water for Injection diluent in a plastic tray (Box of 1 finished product + 1 diluent) | Rx | Friends Pharma (Pvt.) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-17552 | Jan 26, 2032 | |
Merobest 1000Meropenem | 1 g Powder for Injection (I.V.)30 mL-Capacity USP Type I Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal (Box of 1's) | Rx | Mason PharmaIndia | Finstad Inc. | DRP-13733 | Apr 3, 2028 | |
Merobest 500Meropenem | 500 mg Powder for Injection (I.V.)30 mL USP Type I tubular glass vial with 20 mm grey bromo butyl rubber stopper and 20 mm aluminum flip off-seal (Box of 1's) | Rx | Mason PharmaIndia | Finstad Inc | DRP-14683 | Nov 22, 2028 | |
MerocidMeropenem | 1 g Powder for Injection (IV)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Uni MedicolabsIndia | Euro-Med Laboratories Phil., Inc.Importer: Greencore Pharma Inc. | DRP-11927-08 | May 20, 2027 | |
MerocyMeropenem (as trihydrate) | 1 g Powder for Injection (IM/IV)20 mL-capacity moulded soda lime glass vial (Box of 1's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | Cyden Medical Trading Inc.Importer: AMB HK Enterprises Inc. | DRP-9055-04 | Jul 16, 2031 | |
MerodenMeropenem (as trihydrate) | 1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's) | Rx | Daffodills Pharmaceuticals Ltd.India | Cyden Medicale Trading Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-7074-15 | Mar 6, 2027 | |
Merodex 1Meropenem (As Trihydrate) | 1 g Sterile Powder For Injection30 mL USP Type 1 glass vial with grey butyl rubber stopper and sealed with 20 mm Bio-violet color flip-off aluminum seal (Box of 1's) | Rx | KARNATAKA ANTIBIOTICS & PHARMA LTD.India | JACKSON PHARMACEUTICALS INC.Trader: VIDA LABORATORIES PVT. LTD. | DR-XY46452 | Nov 14, 2028 | |
Merodex IIMeropenem (as trihydrate) | 1 g Powder for Injection (IV)Clear and Colorless Glass Vial Sealed with Chlorobutyl Rubber Stopper and Purple Flip-off Seal x 20 mL (5 Vials per Plastic Tray) Box of 10's | Rx | BCWorld Healthcare Co., Ltd.Korea | Jackson Pharmaceuticals Inc.Importer: JLT Pharma Inc. | DRP-6955-04 | Jan 4, 2027 | |
MerogenMeropenem (as trihydrate) | 1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's) | Rx | Daffodills Pharmaceuticals Ltd.India | Genzen Pharmaceutical TradingImporter: Sanimed Pharmaceuticals Inc. | DRP-7074-11 | Mar 6, 2027 | |
MeroGet-500Meropenem | 500 mg Powder For Solution for Injection (IM/IV)10 mL-capacity type I clear glass vial with rubber stopper and pink aluminum flip-off seal (Box of 1's) | Rx | Venus Remedies LimitedIndia | Getmeds Philippines Inc. | DRP-18118 | May 6, 2031 | |
Merogram 1000Meropenem (as trihydrate) | 1 g Powder for IV InjectionUSP Type I Clear Glass Vial (Box of 1's) | Rx | Eugia Pharma Specialities Limited-Unit 2India | Medethix, Inc.Trader: Aurobindo Pharma Limited | DR-XY45730 | Jan 9, 2027 | |
Merogram 500Meropenem | 500 mg Powder for (IV) Injection15 mL Type I Clear Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Flip-off Seal (Box of 1's) | Rx | Eugia Pharma Specialities Limited Unit 2India | Medethix, Inc.Trader: Aurobindo Pharma Ltd. | DR-XY45788 | Feb 23, 2027 | |
Merogrand 1Meropenem (as trihydrate) | 1g Powder for Injection (IV)20 mL Type I clear glass vial + 10 mL ampoule Sterile Water for Injection (as diluent) (Box of 1's) | Rx | Brawn Laboratories LimitedIndia | Grandis Pharma IncorporatedImporter: Sbrg Exim Philippines Inc. | DRP-14001-02 | Jun 1, 2028 | |
MerolevMeropenem | 1 g Powder for Injection (IV)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1 's (Box of 1's) | Rx | Uni Medicolabs Inc.India | HLM Pharmaceutical Inc.Importer: Greencore Pharma Inc. | DRP-11927-02 | May 20, 2027 | |
MeroMateMeropenem (as trihydrate) | 1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's) | Rx | Daffodills Pharmaceuticals Ltd.India | One Technodrug Life Sciences Inc.Importer: Sanimed Pharmaceuticals Inc | DRP-7074-14 | Mar 6, 2027 | |
MeromaxMeropenem (as trihydrate) | 1 g Powder for Injection (I.V.)30 mL Type 1 Glass Vial Sealed with Bromobutyl Rubber Stopper and Aluminum Plastic Cap x 1's (Box of 1's) | Rx | Qilu Antibiotics Pharmaceutical Co. Ltd.China | The Cathay Drug Co., Inc. | DR-XY49168 | Aug 14, 2029 | |
MeromaxMeropenem (as trihydrate) | 500 mg Powder for Injection (I.V.)20 mL Type I Glass Vial Sealed with Bromobutyl Rubber Stopper and Aluminum Plastic Cap x 1's (Box of 1's) | Rx | Qilu Antibiotics Pharmaceutical Co. Ltd.China | The Cathay Drug Co., Inc. | DR-XY49167 | Aug 14, 2029 | |
Meromax 1000Meropenem (as trihydrate) | 1 g Powder for InjectionType I clear and colorless glass vial with gray butyl rubber stopper and aluminum flip-off cap (Box of 1's) | Rx | Biolab Co., Ltd.Thailand | The Cathay Drug Co., Inc. | DR-XY43150 | Jan 13, 2031 | |
Meromax 500Meropenem (as trihydrate) | 500 mg Powder for Injection (I.V.)Type I clear and colorless glass vial with gray butyl rubber stopper and aluminum flip-off cap (Box of 1's) (Box of 1's) | Rx | Biolab Co., Ltd.Thailand | The Cathay Drug Co., Inc. | DR-XY43169 | Jan 13, 2031 | |
Meromax IVMeropenem (as trihydrate) | 1 g Powder for IV InjectionType I Clear Glass Vial (Box of 1's) | Rx | Shenzhen Haibin Pharmaceutical Co., Ltd.China | The Cathay Drug Co., Inc. | DR-XY41588 | Jan 24, 2031 | |
Meromax IVMeropenem (as trihydrate) | 500 mg Powder for IV InjectionType I Clear Glass Vial (Box of 1's) | Rx | Shenzhen Haibin Pharmaceutical Co., Ltd.China | The Cathay Drug Co., Inc. | DR-XY41589 | Jan 26, 2031 | |
MeromedMeropenem (As Trihydrate) | 1g Powder fr Injection IVUSP TYPUSP Type 1 Glass Vial (Box of 1's) | Rx | Maan Pharmaceuticals Ltd.India | Detoxicare Philippines, Inc.Importer: Stangen Pharmaceuticals Pvt. Ltd. | DRP 6439 | Nov 11, 2030 | |
Meronash 1000Meropenem (as trihydrate) | 1g Powder For Injection (Iv)20 mL USP Type I clear glass vial with grey bromobutyl rubber plug and dark green color flip-off aluminum seal (Box of 1's) | Rx | Shamshree Lifesciences Ltd.India | Khriz Pharma Trading Inc. | DR-XY48836 | Aug 3, 2028 | |
Meronash-500Meropenem (as trihydrate) | 500 mg Powder for Injection (I.V.)10 mL USP Type I clear glass vial with grey bromobutyl rubber plug and Turkish-blue color flip-off aluminum seal (Box of 1's) | Rx | Shamshree Lifesciences Ltd.India | Khriz Pharma Trading Inc. | DR-XY49320 | Jan 27, 2030 | |
Meronav-1000Meropenem (as Trihydrate) | 1 g Powder for Injection (I.V.)30 mL USP Type I Clear and Colorless Glass Vial Sealed with 20 mm Grey Bromobutyl Rubber Stopper and Red Flip-Off Seal (Box of 1's) | Rx | Swiss Parenterals Ltd.India | JN Carlo Pharmaceuticals DistributorImporter: AGlobal Care Inc. | DRP-12729-01 | Mar 22, 2027 | |
Meronav-500Meropenem (as trihydrate) | 500 mg Powder for Injection (I.V.)USP Type I Clear Glass Vial (Box of 1's) | Rx | Swiss Parenterals Ltd.India | JN Carlo Pharmaceuticals DistributorImporter: Aglobal Care, Inc. | DRP-12728-01 | Feb 19, 2031 | |
MeronemMeropenem (as trihydrate) | 1 g Powder for Injection (I.V.)In 30 mL type I clear glass vial Box of 1's | Rx | ACS Dobfar S.P.A.Italy | Zuellig Pharma CorporationTrader: Sumitomo Dainippon Pharma Co., Ltd. | DR-XY23416 | Feb 10, 2031 | |
MeronemMeropenem (as trihydrate) | 500 mg Powder for Injection (I.V.)In 20 mL type I clear glass vial (Box of 1's) | Rx | ACS Dobfar S.P.A.Italy | Zuellig Pharma CorporationTrader: Sumitomo Dainippon Pharma Co., Ltd. | DR-XY23414 | Feb 10, 2031 | |
MeronixMeropenem (as trihydrate) | 1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber stopper and pink flip-off seal in a plastic tray (Box of 1's) | Rx | GMH OrganicsIndia | Sanimed Pharmaceuticals Inc. | DRP-7283 | Aug 3, 2027 | |
MeronixMeropenem (as trihydrate) | 500 mg Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber stopper and grey flip-off seal (Box of 1's) | Rx | GMH OrganicsIndia | Sanimed Pharmaceuticals Inc. | DRP-7284 | Aug 3, 2027 | |
MeropMeropenem | 1 g Powder For Injection (IV)20 mL USP Type I Clear Glass Vial with Grey Rubber Stopper and Violet Flip-Off Seal (Box of 1's) | Rx | PT. Darya-Varia Laboratoria TbkIndonesia | UNILAB, Inc. | DRP-11480 | Mar 16, 2027 | |
MeropMeropenem (as trihydrate) | 1 g Powder for Injection (IV)Individually boxed 30 mL-capacity USP Type I clear and colorless glass vial sealed with grey bromobutyl rubber stopper and violet flip-off seal (Box of 10's) | Rx | Zeiss Pharmaceuticals Pvt. Ltd.India | UNILAB, Inc.Importer: Claris Lifesciences Philippines, Inc.Trader: Baxter Pharmaceuticals India Private Limited | DRP-2151-01 | Apr 30, 2027 | |
MeropMeropenem (as Trihydrate) | 500 mg Powder for Injection (IV)USP Type I Clear Colorless Vial (Box of 10's) | Rx | Zeiss Pharmaceuticals Pvt. Ltd.India | UNILAB, Inc.Importer: Claris Lifesciences Philippines, Inc.Trader: Baxter Pharmaceuticals India Private Limited | DR-XY40525 | Jan 13, 2027 | |
MeropMeropenem | 500 mg Powder For Injection (IV)20 mL USP Type I Clear Glass Vial with Grey Rubber Stopper and Violet Flip-Off Seal (Box of 1's) | Rx | PT. Darya-Varia Laboratoria TbkIndonesia | UNILAB, Inc. | DRP-11479 | Mar 16, 2027 | |
MeroparmMeropenem (as trihydrate) | 1 g Powder for Solution for IV Injection/InfusionType III Colorless Glass Vial Sealed with Grey Rubber Stopper and Aluminum Cap x 20 mL (Box of 10's) | Rx | Anfarm Hellas S.AGreece | Aglobal Care, Inc.Trader: Veiovis Lifescience Pvt. Ltd. | DRP-15792 | Sep 18, 2029 | |
MeroparvinMeropenem | 1 g Powder for Injection30 mL- Capacity USP Type I Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal (Box of 1's) | Rx | Mason PharmaIndia | MDB Pharma TradingImporter: Finstad Inc. | DRP-13733-01 | Apr 3, 2028 | |
MeropdicaMeropenem (as trihydrate) | 1 g Powder for Injection (IV)USP Type I Clear and Tubular Glass Vial with Grey Bromo Butyl Rubber Stopper and Sky Blue Plain Flip-off Aluminum Seal x 30 mL (Box of 1's) | Rx | Mepromax Lifesciences Pvt. Ltd.India | Rifemedica CorporationImporter: Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd. | DRP-10557-03 | Dec 15, 2029 | |
MeropegenMeropenem (as trihydrate) | 1 g Powder for Injection (IV)30mL-Type I Colorless Glass Vial Sealed with Halogenated Butyl Rubber Stopper and Aluminum Plastic Cap x 1's (Box of 1's and 10's) | Rx | Haikou Pharmaceutical Factory Co., Ltd.China | Philgen Pharmaceuticals, Inc. | DRP-16270 | Jan 17, 2030 | |
MeropegenMeropenem (as trihydrate) | 500mg Powder for Injection (IV)20mL-Type I Colorless Glass Vial Sealed with gray Halogenated Buty 1 Rubber Stopper and Green Aluminum Plastic Cap x 1's (Box of 1's and 10's) | Rx | Haikou Pharmaceutical Factory Co., Ltd.China | Philgen Pharmaceuticals, Inc. | DRP-16271 | Jan 17, 2030 | |
MeropemMeropenem (as trihydrate) | 1 g Powder for Injection (IV)USP Type III glass vial x 20 mL + Ampoule Sterile Water for Injection x 10 mL (diluent) (Box of 1's) | Rx | Brawn Laboratories LimitedIndia | Detoxicare Phils., Inc.Importer: Ambica International Corporation | DRP-10484-01 | Sep 29, 2029 | |
MeropenMeropenem (as trihydrate) | 1g Powder for Injection (IV)USP Type I clear colorless glass vial, grey bromobutyl rubber stopper and yellow flip-off seal (drug product) + 10 mL Sterile Water for Injection (diluent) (Box of 1 vial drug product + 2 diluent) | Rx | Swiss Parenterals Ltd.India | Endure Medical, Inc. | DRP-1377 | Jul 1, 2028 | |
MeropenMeropenem (as trihydrate) | 1g Powder for Injection (IV)20mL Type I clear glass vial + 10mL ampoule sterile water for injection (as diluent) (Box of 1’s) | Rx | Brawn Laboratories LimitedIndia | Endure Medical, Inc.Importer: Sbrg Exim Philippines Inc. | DRP-14001-01 | Jun 1, 2028 | |
MeropenMeropenem (as Trihydrate) | 500 mg Powder for Injection (IV)Type I Colorless Glass Vial + 10 mL Sterile Water for Injection (as Diluent) (Box of 1's) | Rx | Swiss Parenterals Ltd.India | Endure Medical, Inc. | DR-XY37404 | Jan 25, 2030 | |
MeropevexMeropenem (as trihydrate) | 1g Powder for Injection (IV)12 ml-capacity USP Type 1 molded glass vial in individual box (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Sannovex Pharmaceutical Distributor | DR-XY44217 | Feb 18, 2030 | |
MerophilMeropenem (as trihydrate) | 1 g Powder for Injection (IM/IV)20 mL-Capacity Moulded Soda Lime Glass Vial (Box of 1's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-9055-01 | Jul 20, 2031 | |
MeroproMeropenem (as trihydrate) | 1 g Powder for Injection (I.V.)Clear and Colorless Glass Vial Sealed with Chlorobutyl Rubber Stopper and Purple Flip-off Seal x 30 mL (5 Vials per Plastic Tray) (Box of 10's) | Rx | BCWorld Healthcare Co., Ltd.Republic of Korea | Ellebasy Medicale TradingImporter: JLT Pharma Inc. | DRP-6955-02 | Jan 4, 2032 | |
MeroproMeropenem (as trihydrate) | 500 mg Powder for Injection (IV)20 mL USP Type I Clear and Colorless Glass Vial (Box of 10's) | Rx | BCWorld Healthcare Co., Ltd.Republic of Korea | Ellebasy Medicale TradingImporter: JLT Pharma Inc. | DRP-7859-01 | May 31, 2028 | |
Meroqure-10Meropenem (as Trihydrate) | 1 g Powder for Injection (I.V.)30 mL USP Type I clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber stopper and red flip-off seal (Box of 1's) | Rx | Ameda Pharma Pvt. Ltd.India | Aglobal Care, Inc. | DR-XY45823 | Mar 22, 2027 | |
MEROQURE-10Meropenem (As Trihydrate) | 1 G POWDER FOR INJECTION (I.V.)30 Ml Usp Type I Clear And Colorless Glass Vial Sealed With 20 mm Grey Bromobutyl Rubber Stopper And Red Flip-Off Seal (Box of 1's) | Rx | Swiss Parenterals LimitedIndia | Aglobal Care, Inc. | DRP-12729 | Mar 22, 2032 | |
Meroqure-5Meropenem (as trihydrate) | 500 mg Powder for Injection (I.V.)USP Type I Clear Glass Vial ( (Box of 1's) | Rx | Swiss Parenterals Ltd. (Block-B)India | Aglobal Care, Inc. | DRP-12728 | Feb 19, 2031 | |
MerosalusMeropenem | 1 g Powder for Injection (I.V.)30 mL - Capacity USP Type I Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal (Box of 1's) | Rx | Mason PharmaIndia | Salusa Medical Supplies And Pharmaceuticals IncImporter: Finstad Inc. | DRP-13733-02 | Apr 3, 2028 | |
Merosaph 1000Meropenem (as trihydrate) | 1 g Powder for Injection (I.V.)USP Type I Colorless Glass Vial with Gray Bromo Butyl Rubber Stopper and Aluminum (Box of 1's) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences Inc. | DRP-12071 | Jun 7, 2027 | |
Merosaph 500Meropenem (as trihydrate) | 500 mg Powder for Injection (I.V.)USP Type I Colorless Glass Vial with Gray Bromo Butyl Rubber Stopper and Aluminum Seal X (Box of 1's) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences Inc. | DRP-12072 | Jun 7, 2027 | |
MerostanMeropenem | 1 g Powder for Injection (I.V.)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1's (Box of 1 's) | Rx | Uni MedicolabsIndia | Altor Pharmaceutical Product DistributionImporter: Greencore Pharma Inc. | DRP-11927-07 | May 20, 2027 | |
MerostarMeropenem (as trihydrate) | 1 g Powder for Injection (I.V.)USP Type I Colorless Glass Vial with Gray Bromo Butyl Rubber Stopper and Aluminum Seal (Box of 1’s) | Rx | Kilitch Drugs (India) Ltd.India | Pharmastar Int'l Trading CorpImporter: Nelpa Lifesciences, Inc. | DRP-12071-02 | Jun 7, 2027 | |
MerostarMeropenem (as Trihydrate) | 1g Powder for Injection (I.V.)30mL capacity USP Type III clear and colorless glass vial (Box of 1 of vial) | Rx | Celogen Pharma Pvt. Ltd.India | Pharmastar Int'l Trading Corp. | DRP-6746 | Jul 5, 2031 | |
MerotamMeropenem | 1 g Powder for Injection (I.V.)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Uni Medicolabs, Inc.India | Tamiga Pharmaceuticals SupplyImporter: Greencore Pharma Inc. | DRP-11927-06 | May 20, 2027 | |
MerotamMeropenem | 500 mg Powder for Injection (I.V.)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1 's (Box of 1's) | Rx | Uni MedicolabsIndia | Tamiga Pharmaceuticals SupplyImporter: Greencore Pharma Inc. | DRP-11926-03 | May 20, 2027 | |
MerotechMeropenem (as trihydrate) | 1 g Powder for Injection (IM/IV)20 mL-capacity moulded soda lime glass vial (Box of 1’s) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | SNV Biotech Medicinal Products WholesalingImporter: AMB HK Enterprises Inc. | DRP-9055-05 | Aug 6, 2031 | |
MEROVEX 1000Meropenem (as Trihydrate) | 1 g Powder for Injection (I.V.)Tyoe I Clear glass vial with 20mm grey butyl rubber plug, crimpled aluminum with Black flip off seal (Box of 1's) | Rx | VENUS REMEDIES LIMITEDIndia | VE PHARMA INC.Trader: VEXXA LIFESCIENCES PVT. LTD. | DR-XY46387 | Jun 26, 2028 | |
Merovex 500Meropenem (as Trihydrate) | 500 mg Powder for Injection (IV)Type I Clear Glass Vial with 20 mm Grey Butyl Rubber Plug, Crimped Aluminum with Black Flip-off Seal (Box rimp of 1's) | Rx | Venus Remedies Limited.India | VE Pharma, Inc.Trader: Vexxalife Sciences Pvt. Ltd. | DR-XY46386 | Jun 26, 2028 | |
MerowinMeropenem | 1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's) | Rx | Daffodills Pharmceuticals Ltd.India | Tazio Lifescience Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-7074-02 | Mar 6, 2027 | |
Meroxtar-1000Meropenem (as trihydrate) | 1 g Powder for injection (I.V.)USP Type I Colorless Glass vial with Gray Bromo Butyl Rubber Stopper and Aluminum seal x 1's (Box of 1's) | Rx | Kilitch Drugs (India) Ltd.India | Pharmastar Int'l Trading Corp.Importer: Nelpa Lifesciences, Inc. | DRP-12071-01 | Jun 7, 2027 | |
Meroxtar-500Meropenem (as trihydrate) | 500 mg Powder for injection (I.V)USP Type I Colorless Glass Vial with Gray Bromo Butyl Rubber Stopper and Aluminum Seal x 1's (Box of 1's) | Rx | Kilitch Drugs (India) Ltd.India | Pharmastar Int'l Trading Corp.Importer: Nelpa Lifesciences, Inc. | DRP-12072-01 | Jun 7, 2027 | |
MerozMeropenem (as trihydrate) | 1 g Powder for Injection (I.V.)20 mL transparent vial with gray rubber cap and deep blue flip-off cap (Box of 1's) | Rx | Dongkwang Pharm. Co., Ltd.Republic of Korea | H & B Pharma International Inc. | DRP-16944 | Aug 31, 2028 | |
MerozMeropenem (as trihydrate) | 1g Powder for Injection (I.V.)20 mL USP Type I clear and colorless vial with rubber cap and flip-off cap (Box of 1's) | Rx | Dongkwang Pharm. Co., LtdKorea | PharmAsia-Cuvest Incorporated. | DR-XY48863 | Aug 31, 2028 | |
MerozMeropenem | 500 mg Powder for Injection (I.V.)15 mL USP Type I Clear Glass Vial with Rubber Cap and Dark Green Flip-Off Cap (Box of 1's) | Rx | Dongkwang Pharm. Co., Ltd.Republic of Korea | H & B Pharma International Inc. | DRP-17056 | Mar 16, 2027 | |
MerozMeropenem | 500 mg Powder for injection (IV)15 mL USP Type I Clear Glass Vial with Rubber Cap and Dark Green Flip-Off Cap (Box of 1's) | Rx | Dongkwang Pharma. Co., Ltd.Korea | Pharm Asia-Cuvest, Incorporated | DR-XY47826 | Mar 16, 2027 | |
MerozanMeropenem (as trihydrate) | 1 g Powder for Injection (I.V.)Type III clear and colorless glass vial in individual box NA | Rx | Demo SA Pharmaceutical IndustryGreece | Pharmasia-Cuvest Incorporated | DR-XY39209 | Sep 8, 2030 | |
MerozanMeropenem (as trihydrate) | 500 mg Powder for Injection (I.V.)Type III clear and colorless glass vial in individual box | Rx | Demo SA Pharmaceutical IndustryGreece | Pharmasia-Cuvest Incorporated | DR-XY39208 | Sep 8, 2030 | |
MerozilMeropenem (as trihydrate) | 1 g Powder for Injection (IV)USP Type II Clear Glass Vial Box of 1's | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Global Pharmatrade | DR-XY43651 | Aug 20, 2029 | |
MerozilMeropenem (as Trihydrate) | 500 mg Powder for Injection (IV)Type I Clear and Colorless Glass Vial (Box of 1's) | Rx | Haikou Pharmaceutical Factory Co., Ltd.China | Global Pharmatrade | DR-XY43663 | Aug 22, 2029 | |
MerozoneMeropenem (as trihydrate) | 1 g Powder for Injection (IV)Clear and Colorless Glass Vial Sealed with Chlorobutyl Rubber Stopper and Blue Flip-off Seal x 30mL (Box of 10's) | Rx | BCWorld Healthcare Co., Ltd.Republic of Korea | Marketzone, Inc.Importer: JLT Pharma Inc. | DRP-6955-07 | Jan 4, 2027 | |
MerpenemMeropenem (as trihydrate) | 1 g Powder for Injection (I.V.)20 mL USP Type I tubular clear glass vial with 20mm. grey butyl rubber stopper and 20 mm purple. | Rx | Venus Remedies, LimitedIndia | Triple Tact Import & Export Corp. | DRP-14909 | Feb 7, 2029 | |
MerpenemMeropenem (as trihydrate) | 500 mg Powder for Injection (I.V.)10 mL USP Type I tubular clear glass vial with 20mm grey butyl rubber stopper and 20 mm pink. color flip- off aluminum seal (Box of 1's) | Rx | Venus Remedies, LimitedIndia | Triple Tact Import & Export Corp. | DRP-14910 | Feb 7, 2029 | |
MerpetriMeropenem (as Trihydrate) | 1 g Powder for Injection (IV)USP Type I Clear Glass Vial (Box of 1's) | Rx | Zeiss Pharmaceuticals Pvt. LimitedIndia | Diafarm Inc.Importer: Ambica International Corporation | DRP-6369-04 | Oct 2, 2030 | |
Merprofez 1000Meropenem (as trihydrate) | 1 g Powder for Injection (I.V.)USP Type I Clear and Tubular Glass vial with grey bromo butyl rubber stopper and sky blue plain flip-off aluminum seal x 30 mL Box of 1’s | Rx | Mepromax Lifesciences Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd. | DRP-10557-2 | Dec 15, 2029 | |
Merprofez 500Meropenem (as trihydrate) | 500 mg Powder for Injection (I.V.)USP Type I Clear, Tubular Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal x 20 mL (Box of 1's) | Rx | Mepromax Lifesciences Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd. | DRP-12129-01 | Dec 15, 2029 | |
Merrobe 1000Meropenem (as trihydrate) | 1 g Powder for Injection (I.V.)20 mL USP Type I Transparent Flint Glass Vial (Box of 1’s) | Rx | Zeiss Pharmaceuticals Pvt. Ltd.India | Glenmark Philippines, Inc.Trader: Glenmark Pharmaceuticals, Ltd. | DRP-7691 | Feb 7, 2028 | |
Merrobe 500Meropenem | 500 mg Powder for Injection (I.V.)20 mL USP Type I Transparent Flint Glass Vial (Box of 1’s) | Rx | Zeiss Pharmaceuticals Pvt. Ltd.India | Glenmark Philippines, Inc.Trader: Glenmark Pharmaceuticals, Ltd. | DRP-7690 | Feb 7, 2028 | |
MerrovidMeropenem (as Trihydrate) | 1 g Powder For Solution For Injection (IV)20 mL-capacity USP Type I Clear Colorless Glass Vial with Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal (Box of 1's) | Rx | Brooks Steriscience LimitedIndia | Hovid Inc. | DRP-13349 | Feb 2, 2028 | |
MERROXMeropenem (as trihydrate) | 1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's) | Rx | Daffodills Pharmaceuticals Ltd.India | Sanimed Pharmaceuticals Inc. | DRP-7074 | Mar 6, 2027 | |
MertripenMeropenem (as Trihydrate) | 1 g Powder for Injection (IV)USP Type I Clear Glass Vial (Box of 1's) | Rx | Zeiss Pharmaceuticals Pvt. LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-6369-02 | Apr 5, 2031 | |
MiremMeropenem | 1 g Powder for Injection (IV)30 mL-capacity type I clear glass vial with rubber stopper and alu-plastic cap (Box of 1's and 10's) | Rx | Haikou Pharmaceutical Factory Co., Ltd.China | Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc. | DRP-15565 | Aug 14, 2029 | |
MiremMeropenem | 500 mg Powder for Injection (IV)20 mL-capacity type I clear glass vial with rubber stopper and alu-plastic cap (Box of 1's and 10's) | Rx | Haikou Pharmaceutical Factory Co., Ltd.China | Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc. | DRP-15564 | Aug 14, 2029 | |
MiroMeropenem (as trihydrate) | 1 g Powder for Injection (IV)USP Type III glass vial x 20 mL + Sterile Water for Injection in ampoule x 10 mL (diluent) (Box of 1's) | Rx | Brawn Laboratories LimitedIndia | Pro Medica Inc.Importer: Ambica International Corporation | DRP-10484-02 | Sep 29, 2029 | |
Morep 1000Meropenem (as trihydrate) | 1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's) | Rx | Daffodills Pharmaceuticals Ltd.India | Despina Pharma Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-7074-06 | Mar 6, 2027 | |
Morfenexx 1000Meropenem (as trihydrate) | 1 g Powder for Injection (I.V.)USP Type I Clear and Tubular Glass Vial with Grey Bromo Butyl Rubber Stopper and Sky Blue Plain Flip-Off Aluminum Seal X 30 mL (Box of 1’s) | Rx | Mepromax Lifesciences Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd. | DRP-10557-01 | Dec 15, 2029 | |
Morfenexx 500Meropenem (as trihydrate) | 500 mg Powder for Injection (I.V.)USP Type I Clear, Tubular Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal x 20 mL (Box of 1's) | Rx | Mepromax Lifesciences Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: BDR Pharmaceuticals International Pvt. Ltd. | DRP-12129-02 | Dec 15, 2029 | |
MornemMeropenem | 1 g Powder For Injection (I.V.)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x l's (Box of 1’s) | Rx | Uni Medicolabs, Inc.India | Greencore Pharma, Inc. | DRP-11927 | May 20, 2027 | |
MornemMeropenem | 500 mg Powder for Injection (IV)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x l's (Box of 1’s) | Rx | Uni Medicolabs, Inc.India | Greencore Pharma, Inc. | DRP-11926 | May 20, 2027 | |
MPEN 1000Meropenem (as trihydrate) | 1 g Powder for Injection (IV)USP Type III glass vial x 20 mL + Ampoule Sterile Water for Injection x 10 mL (diluent) (Box of 1's) | Rx | Brawn Laboratories LimitedIndia | GX International, Inc.Importer: Ambica International Corporation | DRP-10484 | Sep 29, 2029 | |
MyrronemMeropenem (as trihydrate) | 1 g Powder for Injection (IV)30-mL capacity Type I clear glass vial with grey chlorobutyl rubber stopper and aluminum-flip off cap (Box of 1's and 10's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-12183 | Jun 27, 2027 | |
MyrronemMeropenem (as trihydrate) | 500 mg Powder for Injection (I.V.)10-mL capacity Type I clear glass vial with grey chlorobutyl rubber stopper and aluminum-flip off cap (Box of 1's and 10's) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-12182 | Feb 4, 2031 | |
NatronemMeropenem (as trihydrate) | 1 g Powder for Injection (IV)USP Type I glass vial (Box of 1’s); USP Type I glass vial (Box of 10’s) | Rx | Samjin Pharmaceutical Co., Ltd.Republic of Korea | Patriot Pharmaceuticals Corporation | DR-XY43762 | Oct 29, 2029 | |
NatronemMeropenem (as trihydrate) | 500 mg Powder for Injection (IV)USP Type I glass vial Box of 1’s; USP Type I glass vial Box of 10’s | Rx | SAMJIN PHARMACEUTICAL CO., LTD.Republic of Korea | Patriot Pharmaceuticals Corporation | DR-XY43763 | Oct 29, 2029 | |
Nemosea-500Meropenem (as trihydrate) | 500 mg Powder for Solution for Intravenous (I.V.) InjectionUSP Type I Clear Glass Vial with Bromobutyl Rubber Stopper and sealed with Aluminum Flip Off Seal x 20 mL (Box of l's) | Rx | Brooks Laboratories LimitedIndia | Seapharma International, Inc. | DRP-12722 | Sep 28, 2027 | |
NoneMeropenem | 1 g Powder for Injection (IV)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Uni Medicolabs, Inc.India | HLM Pharmaceutical Inc.Importer: Greencore Pharma, Inc. | DRP-11927-05 | May 20, 2027 | |
NoneMeropenem (as Trihydrate) | 1 g Powder for Injection (IV)USP Type I Clear Glass Vial (Box of 1's) | Rx | Zeiss Pharmaceuticals Pvt. LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-6369-03 | Oct 2, 2030 | |
NoneMeropenem (as trihydrate) | 1 g Powder for IV InjectionType I clear glass vial (Box of 10's) | Rx | Savior Lifetec Corporation Tainan Branch (Injection Plant)China | Ritemed Phils., Inc. | DR-XY46321 | Apr 26, 2028 | |
NoneMeropenem (as trihydrate) | 1 g Powder for Solution for Injection (I.V.)USP Type II Glass Vial (Box of 1 vial) | Rx | Maxitech Pharma (Pvt.) Ltd.Pakistan | Reta DrugImporter: Accesspoint International Trading Inc. | DRP-15004-01 | Mar 7, 2029 | |
NoneMeropenem (as trihydrate) | 1 g Powder for Solution for Injection (IV)Type III glass vial x 20 mL enclosed with bromobutyl rubber stopper and aluminum grey flip-off seal (Box of 10's) | Rx | ACS Dobfar S.p.A.Italy | OneSource Pharma Solutions, Inc. | DRP-8598 | Dec 20, 2029 | |
NoneMeropenem (as Trihydrate) | 500 mg Powder for I.V. InjectionType I clear glass vial (Box of 10's) | Rx | Savior Lifetec Corporation Tainan Branch (Injection Plant)China | Ritemed Phils., Inc. | DR-XY46320 | Apr 26, 2028 | |
NoneMeropenem (as trihydrate) | 500 mg Powder for Solution for I.V. InjectionColorless Glass Vial Type III Sealed with Grey Rubber Stopper and Aluminum Cap with Plastic Flip-Off Seal 20 mL-capacity (Box of 1 vial) | Rx | Anfarm Hellas S.A.Greece | Saifen Drugs Philippines, Inc.Trader: Pharmaten S.A. | DRP-15232 | Jan 19, 2029 | |
NoneMeropenem (as trihydrate) | 500 mg Powder for Solution for Injection (IV)Type III Glass Vial x 20 mL Enclosed with Bromobutyl Rubber Stopper and Aluminum Purple Flip-Off Seal (Box of 10's) | Rx | ACS Dobfar S.p.A.Italy | OneSource Pharma Solutions, Inc. | DRP-8599 | Dec 20, 2029 | |
One-Mero 1000Meropenem (as trihydrate) | 1 g Powder for Injection (IV)20 mL-capacity Type I Clear Glass Vial with Bromobutyl rubber stopper and Aluminum Flip-off Seal (Box of 1's) | Rx | Brooks Steriscience LimitedIndia | One Dexcel Pharma Inc. | DRP-12537 | Aug 31, 2027 | |
OppironemMeropenem (as Trihydrate) | 1 g Powder for Injection (IV)USP Type I Clear Glass Vial (Box of 1's and 10's) | Rx | Zeiss Pharmaceuticals Pvt. LimitedIndia | Orientphil Pharma Inc.Importer: Ambica International Corporation | DRP-6369-05 | Oct 2, 2030 | |
Orem-PMeropenem (as trihydrate) | 1 g Powder for Injection (IV Infusion)USP Type I Clear and Colorless Glass Vial with Chlorobutyl Rubber Stopper and Aluminium Cap with Red Flip-Off Seal (Box of 10's) | Rx | JW Pharmaceutical CorporationRepublic of Korea | Medirich Pharma Distribution Corp.Importer: H & B Pharma International Inc. | DRP-16414-01 | Jun 23, 2029 | |
PharmanemMeropenem (as trihydrate) | 1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's) | Rx | Daffodills Pharmaceuticals Ltd.India | 228 Pharma TradingImporter: Sanimed Pharmaceuticals Inc. | DRP-7074-12 | Mar 6, 2027 | |
Plemonem 1000Meropenem (as Trihydrate) | 1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 5's) | Rx | Daffodills Pharmaceuticals Ltd.India | Oro Sinai Pharma and General Merchandise, Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-7074-05 | Mar 6, 2027 | |
Plemonem 1000Meropenem (as Trihydrate) | 1 g Powder for Solution for Injection (IV)USP Type I Clear Glass Vial with Purple Flip-off Seal x 30 mL (Box of 1's) | Rx | Brooks Steriscience LimitedIndia | Oro Sinai Pharma and General Merchandise, Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-6527-9 | May 18, 2027 | |
Plemonem 500Meropenem (as Trihydrate) | 500 mg Powder for Solution for Injection (IV)USP Type I Clear Glass Vial with Red Flip-off Seal x 20 mL (Box of 1's) | Rx | Brooks Steriscience LimitedIndia | Oro Sinai Pharma and General Merchandise, Inc.Importer: Sanimed Pharmaceuticals, Inc. | DRP-6528-08 | Feb 12, 2031 | |
PospenemMeropenem (as trihydrate) | 1 g Powder for Injection (IV Infusion)USP Type I Clear and Colorless Glass Vial with Chlorobutyl Rubber Stopper and Aluminium Cap with Red Flip-Off Seal (Box of 10's) | Rx | JW Pharmaceutical CorporationRepublic of Korea | H & B Pharma International Inc. | DRP-16414 | Jun 23, 2029 | |
PospenemMeropenem (as trihydrate) | 500 mg Powder for Injection (IV Infusion)USP Type I Clear Colorless Glass Vial with chlorobutyl rubber stopper and aluminum cap with blue flip-off seal (Box of 10's) | Rx | JW Pharmaceutical CorporationRepublic of Korea | Medlink Marketing Inc. | DR-XY44656 | Jun 17, 2031 | |
ProphemMeropenem (as trihydrate) | 1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's) | Rx | Daffodills Pharmaceuticals Ltd.India | GPC Geo Pharma CorporationImporter: Sanimed Pharmaceuticals Inc. | DRP-7074-03 | Mar 6, 2027 | |
Q-PenemMeropenem (as trihydrate) | 1 g Powder for Injection (IM/IV)20 mL-capacity moulded soda lime glass vial (Box of 1’s) | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | Quad-Gen PharmaceuticalsImporter: AMB HK Enterprises Inc. | DRP-9055-03 | Oct 30, 2031 | |
RetapenemMeropenem (as trihydrate) | 1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber closure with pink flip-off seal (Box of 1's) | Rx | Daffodills Pharmaceuticals Ltd.India | Reta DrugImporter: Sanimed Pharmaceuticals Inc. | DRP-7074-09 | Mar 6, 2027 | |
Rmero-1000Meropenem (as trihydrate) | 1 g Powder for Injection (I.V.)20 mL Type I clear glass vial + 10 mL ampoule Sterile Water for Injection (as diluent) [Box of 1's] | Rx | Brawn Laboratories LimitedIndia | Rifemedica CorporationImporter: SBRG Exim Philippines Inc. | DRP-14001-03 | Jun 1, 2028 | |
RomapenMeropenem (as trihydrate) | 1 g Powder for Injection (I.V.)USP Type I Glass Vial (Box of 1's) | Rx | Zeiss Pharmaceuticals Pvt. Ltd.India | SRS Life Sciences Inc.Trader: SRS Pharmaceuticals Pvt. Ltd. | DR-XY44914 | Jan 25, 2031 | |
RomepenMeropenem (as trihydrate) | 1g Powder for Injection (IV)20 mL-capacity USP Type III clear and colorless glass vial with white flip-off seal Box of 10's and 1's | Rx | Cosmas Research Lab Ltd.India | Endure Medical, Inc. | DR-XY46037 | Sep 27, 2027 | |
RomepenMeropenem (as trihydrate) | 500mg Powder for Injection (I.V.)10mL USP Type III colorless glass vial (Box of 10's and 1's) | Rx | Cosmas Research Lab Ltd.India | Endure Medical, Inc. | DR-XY45926 | Jun 6, 2027 | |
RopenMeropenem (as trihydrate) | 1 g Powder for Injection (IV)Type I Colorless Glass Vial (Box of 1's) | Rx | L.B.S. Laboratory Limited PartnershipThailand | Phil Pharmawealth, Inc. | DR-XY37065 | Nov 24, 2027 | |
RopenefixMeropenem (as Trihydrate) | 1 g Powder for Injection (IV)USP Type I Clear Glass Vial (Box of 1's) | Rx | Zeiss Pharmaceuticals Pvt. LimitedIndia | D&G PharmaImporter: Ambica International Corporation | DRP-6369-01 | Oct 2, 2030 | |
Shepenem-1Meropenem (as trihydrate) | 1 g Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey butyl rubber closure with pink flip-off seal Box of 1's | Rx | Daffodills Pharmaceuticals Ltd.India | Dynasty PharmaceuticalsImporter: Sanimed Pharmaceuticals Inc. | DRP-7074-01 | Mar 6, 2027 | |
Siti - Penem 1000Meropenem (as trihydrate) | 1 g Powder for Injection (IV)20 mL-capacity Type I clear glass vial with bromobutyl rubber stopper and aluminum flip-off seal (Box of 1's) | Rx | Brooks Steriscience LimitedIndia | Sahar International Trading Inc.Importer: One Dexcel Pharma Inc. | DRP-12537-01 | Aug 31, 2027 | |
Siti-Penem 500Meropenem (as trihydrate) | 500 mg Powder for Injection (IV)Type I Clear Glass Vial x 20 mL with bromobutyl rubber stopper and aluminum flip-off seal (Box of 1's) | Rx | Brooks Steriscience LimitedIndia | Sahar International Trading Inc.Importer: One Dexcel Pharma Inc. | DRP-12540-01 | Aug 30, 2027 | |
SitipenamMeropenem (as trihydrate) | 1 g Powder for Injection (I.V.)USP Type I Clear Glass Vial (Box of 1's) | Rx | Intracin PharmaceuticalsIndia | Dynasty PharmaceuticalsImporter: Sahar International Trading, Inc. | DR-XY44090 | Feb 20, 2037 | |
Surinem-1000Meropenem (as trihydrate) | 1g Powder for injection (IV)20 mL-Capacity USP Type I Glass vial with grey bromobutyl rubber stopper and sky blue colored aluminum flip-off seal (Box of 1's) | Rx | Brooks Laboratories Limited.India | Pharma-Surrey International, Inc.Trader: Sherrington Pharmaceuticals (s) Pte., Ltd | DRP-13235 | Jan 6, 2028 | |
Surinem-500Meropenem (as trihydrate) | 500 mg Powder for injection (IV)20 mL-capacity USP Type I glass vial with grey bromobutyl rubber stopper and red colored aluminum flip-off seal (Box of 1's) | Rx | Brooks Laboratories LimitedIndia | Pharma-Surrey International, Inc.Trader: Sherrington Pharmaceuticals (s) Pte, Ltd. | DRP-13216 | Jan 6, 2028 | |
SymeroMeropenem (as trihydrate) | 1 g Powder for Injection (IV)20 mL USP Type III Clear and Colorless Glass Vial Sealed with 20 mm Grey Bromobutyl Rubber Closure with Pink Flip-Off Seal (Box of 1's) | Rx | Daffodills Pharmaceuticals Ltd.India | Hillcross Prime, Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-7074-08 | Mar 6, 2027 | |
SyropenMeropenem (as Trihydrate) | 500 mg Powder for Solution for Injection (IV)USP Type I Clear Glass Vial with Red Flip-off Seal x 20 mL (Box of 1's) | Rx | Brooks Steriscience LimitedIndia | Sanimed Pharmaceuticals, Inc. | DRP-6528 | Feb 12, 2031 | |
TripemMeropenem | 1 g Powder for Injection (IV)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1 's (Box of 1's) | Rx | Uni Medicolabs Inc.India | Triple Tact Import & Export Corp.Importer: Greencore Pharma Inc. | DRP-11927-01 | May 20, 2027 | |
TripemMeropenem | 500 mg Powder for Injection (IV)Type I Round Transparent Colorless Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1 's (Box of 1's) | Rx | Uni MedicolabsIndia | Triple Tact Import & Export Corp.Importer: Greencore Pharma Inc. | DRP-11926-01 | May 20, 2027 | |
Unomero 1000Meropenem | 1g Powder for Injection (I.V.)20 mL USP Type I glass vial with grey bromobutyl rubber stopper and grey aluminum flip-off seal + 10 mL LDPE ampoule of Sterile Water for Injection X 2 (diluent) (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III - Injectables)India | S.M.H.P. Marketing & ConsultancyTrader: Unosource Pharma Ltd. | DRP-11999 | May 27, 2027 | |
VopenemMeropenem (as trihydrate) | 1g Powder for Solution for Injection (IV)Type I clear glass vial x 20 mL with rubber stopper and aluminum purple flip-off seal (Box of 1's) | Rx | Venus Remedies LimitedIndia | Divjot Enterprise Corp. | DR-XY49220 | Sep 24, 2029 | |
WelopenemMeropenem (as trihydrate) | 1 g Powder for Injection (IM/IV)20 mL-capacity moulded soda lime glass vial Box of 1’s | Rx | CSPC Ouyi Pharmaceutical Co., Ltd.China | Connectwell Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-9055-02 | Oct 26, 2031 | |
Winmero-1000Meropenem (as Trihydrate) | 1 g Powder for Injection (IV)USP Type I Clear Glass Vial (Box of 1's and 10's) | Rx | Zeiss Pharmaceuticals Pvt. LimitedIndia | Ambica International Corporation | DRP-6369 | Oct 2, 2030 | |
XanemMeropenem (as Trihydrate) | 1g Powder for Injection (IM/IV)20 mL capacity moulded soda lime glass vial (Box of 1's) | Rx | CSPC Ouyi Pharmaceutical Co. Ltd.China | AMB HK Enterprises Inc. | DRP-9055 | Oct 31, 2031 | |
ZeronemMeropenem (as trihydrate) | 1 g Powder for Injection (IV)Clear and Colorless Glass Vial Sealed with Chlorobutyl Rubber Stopper and Purple Flip-off Seal x 20 mL (5 Vials per Plastic Tray) (Box of 10's) | Rx | BCWorld Healtchare Co., Ltd.Korea | Central West Medicale Inc.Importer: JLT Pharma Inc. | DRP-6955-05 | Jan 4, 2027 | |
Zeronem 500Meropenem (as trihydrate) | 500 mg Powder for Injection (IV)20 mL USP Type I Clear and Colorless Glass Vial (Box of 10's) | Rx | BCWorld Healthcare Co., Ltd.Republic of Korea | Central West Medicale Inc.Importer: JLT Pharma Inc. | DRP-7859-04 | May 31, 2028 | |
(no brand name)Meropenem (as trihydrate) | 500mgl Powder for I.V InjectionColorless Glass Vial Type III Sealed with Grey Rubber Stopper and Aluminum Cap with Plastic Flip-Off Seal 20 mL-capacity (Box of 1 vial) | Rx | Anfarm Hellas S.AGreece | Saifen Drugs Philippines, Inc.Trader: Pharmaten S.A | DR-XY48980 | Jan 19, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Single dose clear glass vials of meropenem for injection containing 500 mg or 1 gram (as the trihydrate blended with anhydrous sodium carbonate for re-constitution) of sterile meropenem powder. 500 mg Meropenem for Injection Vial (3) 1 gram Meropenem for Injection Vial (3)
Warnings/Precautions
- Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving β-lactams. (5.1)
- Severe cutaneous adverse reactions have been reported in patients receiving meropenem. (5.2)
- Seizures and other adverse CNS experiences have been reported during treatment. (5.3)
- Co-administration of meropenem with valproic acid or divalproex sodium reduces the serum concentration of valproic acid potentially increasing the risk of breakthrough seizures. (5.4, 7.2)
- Clostridium difficile -associated diarrhea (ranging from mild diarrhea to fatal colitis) has been reported. Evaluate if diarrhea occurs. (5.5)
- In patients with renal dysfunction, thrombocytopenia has been observed. (5.8)
5.1 Hypersensitivity Reactions
5.1 Hypersensitivity Reactions Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with β-lactams. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe hypersensitivity reactions when treated with another β-lactam.
Before initiating therapy with meropenem, it is important to inquire about previous hypersensitivity reactions to penicillins, cephalosporins, other β-lactams, and other allergens. If an allergic reaction to meropenem occurs, discontinue the drug immediately.
5.2 Severe Cutaneous Adverse Reactions
5.2 Severe Cutaneous Adverse Reactions Severe cutaneous adverse reactions (SCAR) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme (EM) and acute generalized exanthematous pustulosis (AGEP) have been reported in patients receiving meropenem [see Adverse Reactions (6.2)]. If signs and symptoms suggestive of these reactions appear, meropenem should be withdrawn immediately and an alternative treatment should be considered.
5.3 Seizure Potential
5.3 Seizure Potential Seizures and other adverse CNS experiences have been reported during treatment with meropenem. These experiences have occurred most commonly in patients with CNS disorders (e.g., brain lesions or history of seizures) or with bacterial meningitis and/or compromised renal function [see Adverse Reactions (6.1), Drug Interactions (7.2)].
During clinical investigations, 2904 immunocompetent adult patients were treated for non-CNS infections with the overall seizure rate being 0.7% (based on 20 patients with this adverse event). All meropenem-treated patients with seizures had pre-existing contributing factors. Among these are included prior history of seizures or CNS abnormality and concomitant medications with seizure potential.
Dosage adjustment is recommended in patients with advanced age and/or adult patients with creatinine clearance of 50 mL/min or less [see Dosage and Administration (2.2)]. Close adherence to the recommended dosage regimens is urged, especially in patients with known factors that predispose to convulsive activity. Continue anti-convulsant therapy in patients with known seizure disorders.
If focal tremors, myoclonus, or seizures occur, evaluate neurologically, placed on anti-convulsant therapy if not already instituted, and re-examine the dosage of meropenem to determine whether it should be decreased or discontinued.
5.4 Risk of Breakthrough Seizures Due to Drug Interaction with Valproic Acid
5.4 Risk of Breakthrough Seizures Due to Drug Interaction with Valproic Acid The concomitant use of meropenem and valproic acid or divalproex sodium is generally not recommended. Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations.
The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. Increasing the dose of valproic acid or divalproex sodium may not be sufficient to overcome this interaction. Consider administration of antibacterial drugs other than carbapenems to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium.
If administration of meropenem is necessary, consider supplemental anti-convulsant therapy [see Drug Interactions (7.2)].
5.5 Clostridium difficile-associated Diarrhea
5.5 Clostridium difficile-associated Diarrhea Clostridium difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including meropenem, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing isolates of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use.
Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
5.6 Development of Drug-Resistant Bacteria
5.6 Development of Drug-Resistant Bacteria Prescribing meropenem in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
5.7 Overgrowth of Nonsusceptible Organisms
5.7 Overgrowth of Nonsusceptible Organisms As with other broad-spectrum antibacterial drugs, prolonged use of meropenem may result in overgrowth of nonsusceptible organisms. Repeated evaluation of the patient is essential. If superinfection does occur during therapy, appropriate measures should be taken.
5.8 Thrombocytopenia
5.8 Thrombocytopenia In patients with renal impairment, thrombocytopenia has been observed but no clinical bleeding reported [see Dosage and Administration (2.2), Adverse Reactions (6.1), Use in Specific Populations (8.5), (8.6), Clinical Pharmacology (12.3)].
5.9 Potential for Neuromotor Impairment
5.9 Potential for Neuromotor Impairment Alert patients receiving meropenem on an outpatient basis regarding adverse events such as seizures, delirium, headaches and/or paresthesias that could interfere with mental alertness and/or cause motor impairment. Until it is reasonably well established that meropenem is well tolerated, advise patients not to operate machinery or motorized vehicles [see Adverse Reactions (6.1)].
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Valproic acid or divalproex | Avoid | Valproate levels can fall below the therapeutic range; breakthrough seizures. | Generally not recommended; prefer a non-carbapenem; if needed, consider supplemental anticonvulsant. |
| Probenecid | Avoid | Competes for tubular secretion; higher meropenem levels. | Coadministration not recommended. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewed- Co-administration of meropenem with probenecid inhibits renal excretion of meropenem and is therefore not recommended. (7.1)
- The concomitant use of meropenem and valproic acid or divalproex sodium is generally not recommended. Antibacterial drugs other than carbapenems should be considered to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium. (5.4, 7.2)
7.1 Probenecid
7.1 Probenecid Probenecid competes with meropenem for active tubular secretion, resulting in increased plasma concentrations of meropenem. Co-administration of probenecid with meropenem is not recommended.
7.2 Valproic Acid
7.2 Valproic Acid Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures.
Although the mechanism of this interaction is unknown, data from in vitro and animal studies suggest that carbapenems may inhibit the hydrolysis of valproic acid's glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid. If administration of meropenem is necessary, then supplemental anti-convulsant therapy should be considered [see Warnings and Precautions (5.4)].
Adverse reactions
Common
- Headache, nausea, constipation, diarrhea, anemia, vomiting, rash (≥2%)
Serious
- Serious, occasionally fatal hypersensitivity
- Severe cutaneous adverse reactions
- Rhabdomyolysis
- Seizures and other CNS effects
- Clostridioides difficile-associated diarrhea
- Thrombocytopenia (in kidney impairment)
- The following are discussed in greater detail in other sections of labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.2)] Seizure Potential [see Warnings and Precautions (5.3)] Risk of Breakthrough Seizures Due to Drug Interaction with Valproic Acid [see Warnings and Precautions (5.4)] Clostridium difficile - associated Diarrhea [see Warnings and Precautions (5.5)] Development of Drug-Resistant Bacteria [see Warnings and Precautions (5.6)] Overgrowth of Nonsusceptible Organisms [see Warnings and Precautions (5.7)] Thrombocytopenia [see Warnings and Precautions (5.8)] Potential for Neuromotor Impairment [see Warnings and Precautions (5.9)] Most common adverse reactions (2% or less) are: headache, nausea, constipation, diarrhea, anemia, vomiting, and rash. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Savior Lifetec Corporation at 886-6-505-1200 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Adverse Reactions from Clinical Trials
6.1 Adverse Reactions from Clinical Trials Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adult Patients: During clinical investigations, 2904 immunocompetent adult patients were treated for non-CNS infections with meropenem (500 mg or 1 gram every 8 hours).
Deaths in 5 patients were assessed as possibly related to meropenem; 36 (1.2%) patients had meropenem discontinued because of adverse events. Many patients in these trials were severely ill and had multiple background diseases, physiological impairments and were receiving multiple other drug therapies. In the seriously ill patient population, it was not possible to determine the relationship between observed adverse events and therapy with meropenem.
The following adverse reaction frequencies were derived from the clinical trials in the 2904 patients treated with meropenem. Local Adverse Reactions Local adverse events that were reported with meropenem were as follows: Inflammation at the injection site 2.4% Injection site reaction 0.9% Phlebitis/thrombophlebitis 0.8% Pain at the injection site 0.4% Edema at the injection site 0.2% Systemic Adverse Reactions Systemic adverse events that were reported with meropenem occurring in greater than 1.0% of the patients were diarrhea (4.8%), nausea/vomiting (3.6%), headache (2.3%), rash (1.9%), sepsis (1.6%), constipation (1.4%), apnea (1.3%), shock (1.2%), and pruritus (1.2%).
Additional systemic adverse events that were reported with meropenem and occurring in less than or equal to 1.0% but greater than 0.1% of the patients are listed below within each body system in order of decreasing frequency: Bleeding events were seen as follows: gastrointestinal hemorrhage (0.5%), melena (0.3%), epistaxis (0.2%), hemoperitoneum (0.2%). Body as a Whole: pain, abdominal pain, chest pain, fever, back pain, abdominal enlargement, chills, pelvic pain Cardiovascular: heart failure, heart arrest, tachycardia, hypertension, myocardial infarction, pulmonary embolus, bradycardia, hypotension, syncope Digestive System: oral moniliasis, anorexia, cholestatic jaundice/jaundice, flatulence, ileus, hepatic failure, dyspepsia, intestinal obstruction Hemic/Lymphatic: anemia, hypochromic anemia, hypervolemia Metabolic/Nutritional: peripheral edema, hypoxia Nervous System: insomnia, agitation, delirium, confusion, dizziness, seizure, nervousness, paresthesia, hallucinations, somnolence, anxiety, depression, asthenia [see Warnings and Precautions (5.3), (5.9)] Respiratory: respiratory disorder, dyspnea, pleural effusion, asthma, cough increased, lung edema Skin and Appendages: urticaria, sweating, skin ulcer Urogenital System: dysuria, kidney failure, vaginal moniliasis, urinary incontinence Adverse Laboratory Changes Adverse laboratory changes that were reported and occurring in greater than 0.2% of the patients were as follows: Hepatic: increased alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase, lactate dehydrogenase (LDH), and bilirubin Hematologic: increased platelets, increased eosinophils, decreased platelets, decreased hemoglobin, decreased hematocrit, decreased white blood cell (WBC), shortened prothrombin time and shortened partial thromboplastin time, leukocytosis, hypokalemia Renal: increased creatinine and increased blood urea nitrogen (BUN) Urinalysis: presence of red blood cells Complicated Skin and Skin Structure Infections In a study of complicated skin and skin structure infections, the adverse reactions were similar to those listed above.
The most common adverse events occurring in greater than 5% of the patients were: headache (7.8%), nausea (7.8%), constipation (7.0%), diarrhea (7.0%), anemia (5.5%), and pain (5.1%). Adverse events with an incidence of greater than 1%, and not listed above, include: pharyngitis, accidental injury, gastrointestinal disorder, hypoglycemia, peripheral vascular disorder, and pneumonia.
Patients with Renal Impairment: For patients with varying degrees of renal impairment, the incidence of heart failure, kidney failure, seizure and shock reported with meropenem, increased in patients with moderately severe renal impairment (creatinine clearance 10 to 26 mL/min) [see Dosage and Administration (2.2), Warnings and Precautions (5.9), Use in Specific Populations (8.5), (8.6), Clinical Pharmacology (12.3)]. Pediatric Patients: Systemic and Local Adverse Reactions Pediatric Patients with Serious Bacterial Infections (excluding Bacterial Meningitis): Meropenem was studied in 515 pediatric patients (3 months to less than 13 years of age) with serious bacterial infections (excluding meningitis, see next section) at dosages of 10 mg/kg to 20 mg/kg every 8 hours.
The types of systemic and local adverse events seen in these patients are similar to the adults, with the most common adverse events reported as possibly, probably, or definitely related to Meropenem and their rates of occurrence as follows: Diarrhea 3.5% Rash 1.6% Nausea and Vomiting 0.8% Pediatric Patients with Bacterial Meningitis: Meropenem was studied in 321 pediatric patients (3 months to less than 17 years of age) with meningitis at a dosage of 40 mg/kg every 8 hours. The types of systemic and local adverse events seen in these patients are similar to the adults, with the most common adverse reactions reported as possibly, probably, or definitely related to Meropenem and their rates of occurrence as follows: Diarrhea 4.7% Rash (mostly diaper area moniliasis) 3.1% Oral Moniliasis 1.9% Glossitis 1.0% In the meningitis studies, the rates of seizure activity during therapy were comparable between patients with no CNS abnormalities who received meropenem and those who received comparator agents (either cefotaxime or ceftriaxone).
In the meropenem treated group, 12/15 patients with seizures had late onset seizures (defined as occurring on day 3 or later) versus 7/20 in the comparator arm. The meropenem group had a statistically higher number of patients with transient elevation of liver enzymes. Pediatric Patients (Neonates and Infants less than 3 months of Age): Meropenem was studied in 200 neonates and infants less than 3 months of age.
The study was open-label, uncontrolled, 98% of the infants received concomitant medications, and the majority of adverse events were reported in neonates less than 32 weeks gestational age and critically ill at baseline, making it difficult to assess the relationship of the adverse events to meropenem. The adverse reactions seen in these patients that were reported and their rates of occurrence are as follows: Convulsion 5.0% Hyperbilirubinemia (conjugated) 4.5% Vomiting 2.5% Adverse Laboratory Changes in Pediatric Patients: Laboratory changes seen in the pediatric studies, including the meningitis studies, were similar to those reported in the adult studies.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of meropenem. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Worldwide post-marketing adverse reactions not otherwise listed in the Adverse Reactions from Clinical Trials section of this prescribing information and reported as possibly, probably, or definitely drug related are listed within each body system in order of decreasing severity. Blood and Lymphatic System Disorders: agranulocytosis, neutropenia, and leukopenia; a positive direct or indirect Coombs test, and hemolytic anemia.
Immune System Disorders: angioedema. Skin and Subcutaneous Disorders: Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme and acute generalized exanthematous pustulosis.
Adverse reaction frequency tables (US label) US FDA label
| Inflammation at the injection site | 2.4% | |
| Injection site reaction | 0.9% | |
| Phlebitis/thrombophlebitis | 0.8% | |
| Pain at the injection site | 0.4% | |
| Edema at the injection site | 0.2% |
| Diarrhea | 3.5% | |
| Rash | 1.6% | |
| Nausea and Vomiting | 0.8% |
| Diarrhea | 4.7% | |
| Rash (mostly diaper area moniliasis) | 3.1% | |
| Oral Moniliasis | 1.9% | |
| Glossitis | 1.0% |
| Convulsion | 5.0% | |
| Hyperbilirubinemia (conjugated) | 4.5% | |
| Vomiting | 2.5% |
Monitoring parameters
- Seizure risk higher in kidney impairment and central nervous system disease; do not combine with valproate (label class warnings). Kidney
- Creatinine clearance for dosing
- Seizure activity, especially with CNS disorders or kidney impairment
- Valproate levels if coadministered
- Platelet count in kidney impairment
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary There are insufficient human data to establish whether there is a drug-associated risk of major birth defects or miscarriages with meropenem in pregnant women. No fetal toxicity or malformations were observed in pregnant rats and Cynomolgus monkeys administered intravenous meropenem during organogenesis at doses up to 2.4 and 2.3 times the maximum recommended human dose (MRHD) based on body surface area comparison, respectively.
In rats administered intravenous meropenem in late pregnancy and during the lactation period, there were no adverse effects on offspring at doses equivalent to approximately 3.2 times the MRHD based on body surface area comparison (see Data). The background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Meropenem administered to pregnant rats during organogenesis (Gestation Day 6 to Gestation Day 17) in intravenous doses of 240, 500, and 750 mg/kg/day was associated with mild maternal weight loss at all doses, but did not produce malformations or fetal toxicity.
The no-observed-adverse-effect-level (NOAEL) for fetal toxicity in this study was considered to be the high dose of 750 mg/kg/day (equivalent to approximately 2.4 times the MRHD of 1 gram every 8 hours based on body surface area comparison). Meropenem administered intravenously to pregnant Cynomolgus monkeys during organogenesis from Day 20 to 50 after mating at doses of 120, 240, and 360 mg/kg/day did not produce maternal or fetal toxicity at the NOAEL dose of 360 mg/kg/day (approximately 2.3 times the MRHD based on body surface area comparison).
In a peri-postnatal study in rats described in the published literature 2, intravenous meropenem was administered to dams from Gestation Day 17 until Lactation Day 21 at doses of 240, 500, and 1000 mg/kg/day. There were no adverse effects in the dams and no adverse effects in the first generation offspring (including developmental, behavioral, and functional assessments and reproductive parameters) except that female offspring exhibited lowered body weights which continued during gestation and nursing of the second generation offspring.
Second generation offspring showed no meropenem-related effects. The NOAEL value was considered to be 1000 mg/kg/day (approximately 3.2 times the MRHD based on body surface area comparisons).
Mechanism of action
12.1 Mechanism of Action Meropenem is an antibacterial drug [see Microbiology (12.4)].
Mechanism of Action The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem penetrates the cell wall of most gram-positive and gram-negative bacteria to bind penicillin-binding-protein (PBP) targets. Meropenem binds to PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2 and 4 of Staphylococcus aureus.
Bactericidal concentrations (defined as a 3 log 10 reduction in cell counts within 12 hours to 24 hours) are typically 1 to 2 times the bacteriostatic concentrations of meropenem, with the exception of Listeria monocytogenes, against which lethal activity is not observed. Meropenem does not have in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant Staphylococcus epidermidis (MRSE).
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics The percentage of time of a dosing interval that unbound plasma concentration of meropenem exceeds the meropenem minimum inhibitory concentration (MIC) against the infecting organism has been shown to best correlate with efficacy in animal and in vitro models of infection.
Pharmacokinetics
Key PK parameters
| Time to peak | End of 30-minute infusion: about 23 mcg/mL (500 mg) and 49 mcg/mL (1 g); 5-minute bolus: about 45 mcg/mL (500 mg) and 112 mcg/mL (1 g) |
|---|---|
| Half-life | About 1 hour |
| Half-life in kidney failure (ESKD) kidney | About 6.8 hours in ESKD (vs 0.9 hours healthy; Christensson 1992); 7.0 hours off dialysis, 2.9 hours during hemodialysis (Chimata 1993) |
| Protein binding | About 2% |
| Metabolism (CYP, transporters) | One microbiologically inactive metabolite (about 28% of dose) |
| Active metabolites | None |
| Renal excretion kidney | About 70% (50% to 75%) unchanged in urine within 12 hours |
| Dialyzability kidney | Yes: readily dialyzable and effectively removed by hemodialysis (label); dialysis clearance about 79 mL/min/1.73 m2 (Christensson 1992). |
Excretion Meropenem is primarily excreted unchanged by the kidneys.
Approximately 70% (50% - 75%) of the dose is excreted unchanged within 12 hours.
The measured renal clearance and the effect of probenecid show that meropenem undergoes both filtration and tubular secretion.
Urinary concentrations of meropenem in excess of 10 mcg/mL are maintained for up to 5 hours after a 500 mg dose.
The elimination half-life for meropenem was approximately 1.5 hours in pediatric patients of age 3 months to 2 years.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Plasma Concentrations At the end of a 30-minute intravenous infusion of a single dose of meropenem in healthy volunteers, mean peak plasma concentrations of meropenem are approximately 23 mcg/mL (range 14 to 26) for the 500 mg dose and 49 mcg/mL (range 39 to 58) for the 1 gram dose. A 5-minute intravenous bolus injection of meropenem in healthy volunteers results in mean peak plasma concentrations of approximately 45 mcg/mL (range 18 to 65) for the 500 mg dose and 112 mcg/mL (range 83 to 140) for the 1 gram dose.
Following intravenous doses of 500 mg, mean plasma concentrations of meropenem usually decline to approximately 1 mcg/mL at 6 hours after administration. No accumulation of meropenem in plasma was observed with regimens using 500 mg administered every 8 hours or 1 gram administered every 6 hours in healthy volunteers with normal renal function.
Distribution The plasma protein binding of meropenem is approximately 2%. After a single intravenous dose of meropenem, the highest mean concentrations of meropenem were found in tissues and fluids at 1 hour (0.5 hours to 1.5 hours) after the start of infusion, except where indicated in the tissues and fluids listed in Table 5 below.
Table 5: Meropenem Concentrations in Selected Tissues (Highest Concentrations Reported) Tissue Intravenous. Dose (gram) Number of Samples Mean [mcg/mL or mcg/(gram)] at 1 hour unless otherwise noted. Range [mcg/mL or mcg/(gram)] Endometrium 0.5 7 4.2 1.7-10.2 Myometrium 0.5 15 3.8 0.4-8.1 Ovary 0.5 8 2.8 0.8-4.8 Cervix 0.5 2 7 5.4-8.5 Fallopian tube 0.5 9 1.7 0.3-3.4 Skin 0.5 22 3.3 0.5-12.6 Interstitial fluid obtained from blister fluid. 0.5 9 5.5 3.2-8.6 Skin 1 10 5.3 1.3-16.7 Interstitial fluid 1 5 26.3 20.9-37.4 Colon 1 2 2.6 2.5-2.7 Bile 1 7 14.6 (3 hours) 4-25.7 Gall bladder 1 1 — 3.9 Peritoneal fluid 1 9 30.2 7.4-54.6 Lung 1 2 4.8 (2 hours) 1.4-8.2 Bronchial mucosa 1 7 4.5 1.3-11.1 Muscle 1 2 6.1 (2 hours) 5.3-6.9 Fascia 1 9 8.8 1.5-20 Heart valves 1 7 9.7 6.4-12.1 Myocardium 1 10 15.5 5.2-25.5 CSF (inflamed) 20 mg/kg in pediatric patients of age 5 months to 8 years. 40 mg/kg in pediatric patients of age 1 months to 15 years. 8 5 1.1 (2 hours) 3.3 (3 hours) 0.2-2.8 0.9-6.5 CSF (uninflamed) 1 4 0.2 (2 hours) 0.1-0.3 Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
Metabolism There is one metabolite of meropenem that is microbiologically inactive. Excretion Meropenem is primarily excreted unchanged by the kidneys. Approximately 70% (50% - 75%) of the dose is excreted unchanged within 12 hours. A further 28% is recovered as the microbiologically inactive metabolite. Fecal elimination represents only approximately 2% of the dose.
The measured renal clearance and the effect of probenecid show that meropenem undergoes both filtration and tubular secretion. Urinary concentrations of meropenem in excess of 10 mcg/mL are maintained for up to 5 hours after a 500 mg dose. Specific Populations Patients with Renal Impairment Pharmacokinetic studies with meropenem in patients with renal impairment have shown that the plasma clearance of meropenem correlates with creatinine clearance.
Dosage adjustments are necessary in subjects with renal impairment (creatinine clearance 50 mL/min or less) [see Dosage and Administration (2.2), Use in Specific Populations (8.6)]. Meropenem is hemodialyzable. However, there is no information on the usefulness of hemodialysis to treat overdosage [see Overdosage (10)]. Patients with Hepatic Impairment A pharmacokinetic study with meropenem in patients with hepatic impairment has shown no effects of liver disease on the pharmacokinetics of meropenem.
Geriatric Patients A pharmacokinetic study with meropenem in elderly patients with renal impairment showed a reduction in plasma clearance of meropenem that correlates with age-associated reduction in creatinine clearance. Pediatric Patients The pharmacokinetics of meropenem, in pediatric patients 2 years of age or older, are similar to those in adults.
The elimination half-life for meropenem was approximately 1.5 hours in pediatric patients of age 3 months to 2 years. The pharmacokinetics of meropenem in patients less than 3 months of age receiving combination antibacterial drug therapy are given below. Table 6: Meropenem Pharmacokinetic Parameters in Patients Less Than 3 Months of Age Values are derived from a population pharmacokinetic analysis of sparse data GA less than 32 weeks PNA less than 2 weeks (20mg/kg every 12 hours) GA less than 32 weeks PNA 2 weeks or older (20mg/kg every 8 hours) GA 32 weeks or older PNA less than 2 weeks (20mg/kg every 8 hours) GA 32 weeks or older PNA 2 weeks or older (30mg/kg every 8 hours) Overall CL (L/h/kg) 0.089 0.122 0.135 0.202 0.119 V (L/kg) 0.489 0.467 0.463 0.451 0.468 AUC 0-24 (mcg-h/mL) 448 491 445 444 467 C max (mcg/mL) 44.3 46.5 44.9 61 46.9 C min (mcg/mL) 5.36 6.65 4.84 2.1 5.65 T 1/2 (h) 3.82 2.68 2.33 1.58 2.68 Drug Interactions Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem.
Following administration of probenecid with meropenem, the mean systemic exposure increased 56% and the mean elimination half-life increased 38% [see Drug Interactions (7.1)].
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Meropenem 1 g Vial | ₱143.22–₱840.00Reference ₱156.45 | per vial | DPRI procurement range |
| Meropenem 500 mg Vial | ₱97.33–₱540.00Reference ₱104.39 | per vial | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Meropenem (as trihydrate) |
| PNF listing | Inj.: 500 mg and 1 g powder, vial (IV)Restrictions: Reserve antimicrobial (PNF) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. MEROPENEM · Civica, Inc [US FDA-approved label, version 7, November 2, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0075b72-c3cc-f844-e053-2a95a90a417f
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Civica, Inc. (2026). Meropenem for injection, USP (meropenem; single-dose vials, 500 mg and 1 g) [Prescribing information; US FDA-approved label, ANDA206086, set ID b0075b72-c3cc-f844-e053-2a95a90a417f, version effective November 2, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0075b72-c3cc-f844-e053-2a95a90a417f
- Li, L., Li, X., Xia, Y., Chu, Y., Zhong, H., Li, J., Liang, P., Bu, Y., Zhao, R., Liao, Y., Yang, P., Lu, X., & Jiang, S. (2020). Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Frontiers in Pharmacology, 11, Article 786. https://doi.org/10.3389/fphar.2020.00786
- Shaw, A. R., & Mueller, B. A. (2017). Antibiotic dosing in continuous renal replacement therapy. Advances in Chronic Kidney Disease, 24(4), 219–227. https://doi.org/10.1053/j.ackd.2017.05.004
- Roberts, J. A., Abdul-Aziz, M. H., Davis, J. S., Dulhunty, J. M., Cotta, M. O., Myburgh, J., Bellomo, R., & Lipman, J. (2016). Continuous versus intermittent β-lactam infusion in severe sepsis: A meta-analysis of individual patient data from randomized trials. American Journal of Respiratory and Critical Care Medicine, 194(6), 681–691. https://doi.org/10.1164/rccm.201601-0024OC
- Dulhunty, J. M., Brett, S. J., De Waele, J. J., Rajbhandari, D., Billot, L., Cotta, M. O., Davis, J. S., Finfer, S., Hammond, N. E., Knowles, S., Liu, X., McGuinness, S., Mysore, J., Paterson, D. L., Peake, S., Rhodes, A., Roberts, J. A., Roger, C., Shirwadkar, C., ... Lipman, J. (2024). Continuous vs intermittent β-lactam antibiotic infusions in critically ill patients with sepsis: The BLING III randomized clinical trial. JAMA, 332(8), 629–637. https://doi.org/10.1001/jama.2024.9779
- Li, P. K.-T., Chow, K. M., Cho, Y., Fan, S., Figueiredo, A. E., Harris, T., Kanjanabuch, T., Kim, Y.-L., Madero, M., Malyszko, J., Mehrotra, R., Okpechi, I. G., Perl, J., Piraino, B., Runnegar, N., Teitelbaum, I., Wong, J. K.-W., Yu, X., & Johnson, D. W. (2022). ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 42(2), 110–153. https://doi.org/10.1177/08968608221080586
- Tsai, Y. V., Soto, C., Crawford, G., & Dzintars, K. (2025). Important antimicrobial dosing considerations for transitions of care: Focus on thrice-weekly dosing in hemodialysis. American Journal of Health-System Pharmacy, 82(4), 203–210. https://doi.org/10.1093/ajhp/zxae259
- Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287
- Christensson, B. A., Nilsson-Ehle, I., Hutchison, M., Haworth, S. J., Oqvist, B., & Norrby, S. R. (1992). Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrobial Agents and Chemotherapy, 36(7), 1532–1537. https://doi.org/10.1128/AAC.36.7.1532
- Chimata, M., Nagase, M., Suzuki, Y., Shimomura, M., & Kakuta, S. (1993). Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrobial Agents and Chemotherapy, 37(2), 229–233. https://doi.org/10.1128/AAC.37.2.229
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026.
Last updated: .